Introduction {#s1}
============

Platelets are highly reactive anucleated cell fragments, which are produced by megakaryocytes (MKs) in the bone marrow, spleen and lungs. In an intact vasculature, platelets circulate in the blood stream for 7--10 days and are finally cleared by the reticulo-endothelial system in the spleen and liver. Upon vascular injury, however, platelets adhere to the exposed vascular extracellular matrix (ECM), become activated and form a hemostatic plug that seals the wound. Platelet activation must be tightly regulated to avoid hyperactivity and indiscriminate vessel occlusion ([@bib10]; [@bib32]). The mechanisms that inhibit platelet activation include extrinsic factors, such as endothelial-derived nitric oxide and prostacyclin, and intrinsic factors, such as immunoreceptor tyrosine-based inhibition motif (ITIM)-containing receptors ([@bib15]; [@bib59]).

G6b-B is a unique platelet ITIM-containing receptor that is highly expressed in mature MKs and platelets ([@bib15]; [@bib72]). It is a type I transmembrane protein that consists of a single N-glycosylated immunoglobulin-variable (IgV)-like domain in its extracellular region, a single transmembrane domain and a cytoplasmic tail containing an ITIM and an immunoreceptor tyrosine-based switch motif (ITSM). The central tyrosine residues embedded in the consensus sequences of the ITIM (\[I/V/L\]xYxx\[V/L\]) and ITSM (\[T\]xYxx\[V/I\]) become phosphorylated by Src family kinases (SFKs) and subsequently act as docking sites for the Src homology 2 (SH2) domain-containing protein-tyrosine phosphatases (Shp)1 and 2 ([@bib50]; [@bib72]). The canonical mode of action of ITIM-containing receptors is to position these phosphatases, as well as the SH2 domain-containing inositol polyphosphate 5-phosphatase 1 (SHIP1) in close proximity to ITAM-containing receptors, allowing them to dephosphorylate key components of the ITAM signaling pathway and to attenuate activation signals. The inhibitory function of G6b-B has been demonstrated in a heterologous cell system, by antibody-mediated crosslinking of the receptor in platelets and G6b-B knockout (*KO*) mouse models ([@bib50]; [@bib55]; [@bib60]). Findings from these mice demonstrated that the function of G6b-B goes beyond inhibiting signaling from ITAM-containing receptors ([@bib51]; [@bib50]). These mice develop a severe macrothrombocytopenia, myelofibrosis, and aberrant megakaryocyte and platelet function, establishing G6b-B as a critical regulator of platelet activation and production. This phenotype was also observed in a G6b-B loss-of-function mouse model (*Mpig6b^diYF^*) in which the tyrosine residues within the ITIM and ITSM were mutated to phenylalanine residues, abrogating the binding of Shp1 and Shp2 to G6b-B and downstream signaling ([@bib29]). Moreover, expression of human G6b-B in mouse platelets rescued the phenotype of G6b-B-deficient mice, demonstrating that human and mouse G6b-B exert the same physiological functions ([@bib31]). Importantly, null and loss-of-function mutations in human G6b-B have been reported to recapitulate key features of the *Mpig6b* KO and loss-of-function mouse phenotypes, including a severe macrothrombocytopenia, MK clusters in the bone marrow and myelofibrosis ([@bib31]; [@bib53]). Despite the vital role of G6b-B in regulating platelet production and function, its physiological ligand was not known. Although a previous study demonstrated that G6b-B binds to the glycosaminoglycan (GAG) heparin, the functional significance of this interaction was not known ([@bib18]).

Proteoglycans comprise a heterogeneous family of macromolecules, consisting of a core protein and associated unbranched GAG side-chains. Heparan sulfates (HS) are a specific subgroup of GAGs, defined by their basic disaccharide unit. They are structurally related to heparin, which is produced as a macromolecular proteoglycan by tissue-resident mast cells ([@bib42]) and which, following chemical or enzymatic processing, serves as an anti-coagulant ([@bib12]; [@bib54]). One of the best studied and abundant HS proteoglycans is perlecan, which is synthesized and secreted by endothelial and smooth muscle cells into the vessel wall. It is comprised of a large 400-kDa core protein and has three HS chains attached to its N-terminus. A number of proteins reportedly interact with the HS chains and protein core of perlecan, among them are structural components of the ECM, including laminin, collagen IV and fibronectin, and fibroblast growth factor-2 ([@bib62]; [@bib80]). Of note, the proteolytically released C-terminal fragment of perlecan, called endorepellin, binds to integrin α2β1 and enhances collagen-mediated platelet activation ([@bib6]). Perlecan has also been shown to exert anti-thrombotic properties in an ovine vascular graft model through its HS side-chains, although the underlying mechanism has not been defined ([@bib46]).

In this study, we identified the physiological ligand of G6b-B, the molecular basis of the G6b-B ligand interactions and the mechanism underlying physiological effects. Our findings demonstrate that G6b-B binds the HS chains of perlecan, as well as to heparin, eliciting functional responses in MKs and platelets. Moreover, we also show that a cross-linked, semisynthetic form of heparin, called anti-platelet anti-coagulant (APAC) ([@bib43]), beyond inhibiting collagen-mediated platelet aggregation, induces robust phosphorylation and downstream signaling of G6b-B. Collectively, these results reveal that HSs regulate G6b-B signaling and function, providing a novel mechanism by which MK and platelet function is regulated.

Results {#s2}
=======

Identification of perlecan as a ligand of G6b-B {#s2-1}
-----------------------------------------------

To identify the tissue expressing the physiological ligand of G6b-B, we generated a recombinant mouse G6b-B Fc-fusion protein (mG6b-B-Fc), consisting of the murine G6b-B ectodomain and the human IgG-Fc tail (to mediate dimer formation), which we used to stain frozen mouse tissue sections. We consistently observed prominent staining in large vessels, including the vena cava and aorta, and also in smaller vessels in the liver and spleen, that were not observed with the negative control (IgG-Fc) ([Figure 1](#fig1){ref-type="fig"}), suggesting the presence of G6b-B ligand in vessel walls. The highly vascularized bone marrow sections showed a more diffuse staining, indicative of the presence of the ligand in the bone marrow ECM ([Figure 1](#fig1){ref-type="fig"}).

![Prominent binding of mG6b-B-Fc to the vessel wall.\
Immunohistochemistry staining of frozen mouse tissue sections with mG6b-B-Fc or human IgG-Fc fragments (control). Bound protein was visualized using a secondary anti-human-Fc-HRP antibody and DAB substrate, prior to counterstaining with hematoxylin. The images were captured by a Zeiss Axio Scan.Z1 slidescanner, and images were exported using the Zeiss Zen software. (**A**) Overview and (**B**) zoomed-in images for the indicated tissues. lu, vessel lumen. Larger overview sections of the tissues are shown in [Figure 1---figure supplements 1](#fig1s1){ref-type="fig"}, [2](#fig1s2){ref-type="fig"}.](elife-46840-fig1){#fig1}

Because of the strong signals and easy accessibility of the vena cava, we incubated vena cava homogenates with mG6b-B-Fc and protein G sepharose beads to precipitate and identify G6b-B binding partners. SDS-PAGE and colloidal coomassie staining revealed bands of high molecular weight that were absent in the negative control (IgG-Fc pulldown, [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). Bands were excised and proteins identified by mass spectrometry, revealing basal membrane-specific HS proteoglycan (HSPG) core protein or perlecan as the most abundant protein specifically pulled-down with mG6b-B-Fc ([Table 1](#table1){ref-type="table"}).

10.7554/eLife.46840.006

###### List of proteins immunoprecipitated with mG6b-B-Fc from vena cava lysates

10.7554/eLife.46840.007Table 1---source data 1.Mass spectrometry results for proteins precipitated from vena cava lysates with mG6b-B-Fc.

10.7554/eLife.46840.008Table 1---source data 2.Mass spectrometry results for proteins precipitated from vena cava lysates with Fc control protein.

10.7554/eLife.46840.009Table 1---source data 3.Mass spectrometry results for the proteins detected at the respective height after loading mG6b-B-Fc only (no vena cava lysate).

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Accession number   Name                                                                              Peptides   Protein score   Protein score negative control   FE
  ------------------ --------------------------------------------------------------------------------- ---------- --------------- -------------------------------- ------
  E9PZ16             Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan)   131        607.22          n.d.                             

  *E9QPE7*           *Myosin-11*                                                                       *103*      *468.02*        *719.71*                         0.7

  F8VQJ3             Laminin subunit gamma-1                                                           75         434.43          9.66                             45.0

  *Q5SX39*           *Myosin-4*                                                                        *80*       *328.62*        *587.14*                         0.6

  *Q8VDD5*           *Myosin-9*                                                                        *81*       *318.18*        *513.68*                         0.6

  P97927             Laminin subunit alpha-4                                                           56         285.20          n.d.                             

  Q61292             Laminin subunit beta-2                                                            63         262.37          n.d.                             

  *B2RWX0*           *Myosin, heavy polypeptide 1*,\                                                   *61*       *244.66*        *446.14*                         0.5
                     *skeletal muscle, adult*                                                                                                                      

  P02469             Laminin subunit beta-1                                                            57         236.87          n.d.                             

  J3QQ16             Protein Col6a3                                                                    61         232.99          14.76                            15.8

  *G3UW82*           *MCG140437*, *isoform CRA_d*                                                      54         *214.75*        378.87                           0.6

  *B7FAU9*           *Filamin, alpha*                                                                  58         202.67          139.51                           1.5

  Q3UHL6             Putative uncharacterized protein --- fibronectin                                  48         192.76          n.d.                             

  Q9JKF1             *Ras GTPase-activating-like protein IQGAP1*                                       31         107.79          68.57                            1.6

  M0QWP1             Agrin                                                                             21         84.47           n.d.                             

  P19096             Fatty acid synthase                                                               27         74.68           23.81                            3.1

  Q61001             Laminin subunit alpha-5                                                           23         73.24           n.d.                             

  E9QPX1             Collagen alpha-1(XVIII) chain                                                     16         59.16           n.d.                             

  A2AJY2             Collagen alpha-1(XV) chain                                                        14         53.53           n.d.                             

  B7ZNH7             Collagen alpha-1(XIV) chain                                                       15         43.27           3.09                             14.0

  *P26039*           *Talin-1*                                                                         *11*       *42.29*         *29.93*                          1.4
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

Fold enrichment (FE)=score G6b-B-FC precipitation/score negative control; n.d. = not detectable. Proteins that are prominently present in the negative control (FE \< 2) are shown in italic. The protein score was calculated using the SEQUEST HT search algorithm and is the sum of all peptide Xcorr values above the specified score threshold (0.8 + peptide_charge × peptide_relevance_factor where peptide_relevance_factor is a parameter with a default value of 0.4). The full data set, including the mass spectrometry result for the respective band of a G6b-B-FC only sample, is found in [Table 1---source data 1](#table1sdata1){ref-type="supplementary-material"}--[3](#table1sdata3){ref-type="supplementary-material"}. A picture of a gel and the bands excised for mass-spectrometric analysis are shown in [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}.

The interaction with perlecan was verified using an in vitro binding assay, which measured the binding of soluble mG6b-B-Fc to immobilized molecules. mG6b-B-Fc bound robustly to perlecan, but not to bovine serum albumin (BSA) (control) or other ECM molecules, including collagen I and IV, various forms of laminin (111, 411, 421, 511 and 521), fibronectin or the related and recombinantly expressed HSPGs syndecan-2 or agrin ([Figure 2A](#fig2){ref-type="fig"}). Hence, the laminin and collagen identified by G6b-B pulldown and mass spectrometry ([Table 1](#table1){ref-type="table"}) most probably represented perlecan-associated proteins ([@bib2]) rather than direct binding partners of G6b-B. Human G6b-B-Fc (huG6b-B-Fc) showed binding characteristics similar to those of mG6b-B-Fc ([Figure 2A](#fig2){ref-type="fig"}).

![G6b-B-Fc binds to heparan sulfate side-chains of perlecan.\
(**A**) 96-well plates were coated with the indicated substrates (5 µg/ml) and incubated with mouse G6b-B-Fc (10 µg/ml), human G6b-B-Fc (30 µg/ml) or Fc-control (10 µg/ml). Bound protein was detected with an anti-human-Fc-HRP antibody and 3,3′,5,5′-tetramethylbenzidine (TMB) substrate. n = 2--4; SA, streptavidin. (**B**) Perlecan and bovine serum albumin (BSA) were treated or not with heparinase III (5 mU/ml) prior to blocking, and mG6b-B-Fc binding was measured. n = 4. (**C**) mG6b-B binding to immobilized perlecan was measured in the presence of the indicated concentrations of heparin and heparan sulfate. n = 3. P-values were calculated using ordinary one-way ANOVA with Dunnett's post-hoc test and asterisks denote statistical significance compared to the respective control. \*\*\*, p\<0.001. Source files of all binding assays are available in [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.46840.012Figure 2---source data 1.Source data for graphs shown in [Figure 2A--C](#fig2){ref-type="fig"}.](elife-46840-fig2){#fig2}

Treatment of perlecan with the enzyme heparinase III, which removes the HS side-chains, significantly reduced G6b-B binding to immobilized perlecan ([Figure 2B](#fig2){ref-type="fig"}), indicating that G6b-B binds to the HS side-chains rather than the protein core. This observation was further supported by a competition assay, in which the addition of soluble HS inhibited the binding of G6b-B to immobilized perlecan ([Figure 2C](#fig2){ref-type="fig"}). Of note, unfractionated heparin, which is closely related to HS, also interfered with G6b-B binding to perlecan and streptavidin-immobilized biotin-conjugated heparin and also bound directly to G6b-B-Fc ([Figure 2A](#fig2){ref-type="fig"}).

To gain further insights into the structural requirements of the G6b-B--ligand interaction, we tested heparin oligomers of different lengths (4, 8, 12 and 20 saccharide units, degree of polymerization (dp)4, dp8, dp12 and dp20, respectively) and selectively desulfated heparin molecules for their binding to G6b-B. In a competition assay, only oligomers of at least eight saccharides were able to block binding of G6b-B to heparin-biotin partially, suggesting that this is the minimum length required for this interaction ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). In addition, high sulfation of the glycan was found to be important for G6b-B binding, as a loss of occupancy of one sulfation site resulted in a significant drop in the ability of the oligomer to block G6b-B binding to native heparin ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}).

As the binding assay results suggested that the G6b-B ligand was primarily composed of HS glycans, we opted to confirm and extend these finding using a genome-scale cell-based CRISPR KO screening approach to identify all of the genes that are required for the synthesis and cell surface display of the G6b-B ligand ([@bib74]). We observed that a highly avid recombinant G6b-B molecule, consisting of the entire ectodomain of biotinylated human G6b-B clustered around phycoerythrin (PE)-conjugated streptavidin, robustly stained several human cell lines, providing the basis for a cellular genetic screen ([Figure 3A](#fig3){ref-type="fig"}). A genome-wide mutant cell library was generated by transducing Cas9-expressing HEK293 cells with a library of lentiviruses, each encoding a single gRNA from a pool of 90,709 individual gRNAs targeting 18,009 human genes ([@bib74]). Transduced cells that had lost the ability to bind to the recombinant protein were isolated using fluorescent-activated cell sorting, and genes that are required for cell surface binding of G6b-B were identified by comparing the relative abundance of gRNAs in the sorted versus unsorted control populations ([@bib44]). Using this strategy, we unambiguously identified many genes that are required for HS biosynthesis, beginning with the generation of the tetrasaccharide linkage on the serine residue of the protein backbone (*B3GAT3*, *XYLT2*, *B4GALT7*), the commitment towards the HS pathway (*EXTL3*), HS chain polymerization (*EXT1/2*), and HS chain modification (*NDST1*, *HS2ST1*) ([Figure 3B](#fig3){ref-type="fig"}). Of particular note, genes encoding the enzymes chondroitin sulfate N-acetylgalactosaminyltransferase 1 and 2 (*CSGALNACT1/2*), which are essential for the commitment towards the biosynthesis of chondroitin sulfate chains, were not identified, demonstrating that G6b-B binding to HEK293 cells is mediated by HS, but not by chondroitin sulfate ([Figure 3B](#fig3){ref-type="fig"}). Moreover, the addition of heparin, but not chondroitin sulfate, inhibited G6b-B binding to HEK293 cells ([Figure 3C](#fig3){ref-type="fig"}). We also identified *SLC35B2* (Solute Carrier Family 35 Member B2), a gene encoding a transporter protein that translocates 3′-phosphoadenosine-5′-phosphosulfate from the cytosol into the Golgi apparatus, where it is used as a sulfate donor for the sulfation of glycoproteins, proteoglycans, and glycolipids. We validated the involvement of sulfated HSs in mediating G6b-B binding to cells by individually targeting *SLC35B2* and were able to demonstrate that this led to a loss of G6b-B binding relative to the parental cell line ([Figure 3D](#fig3){ref-type="fig"}). Together, this genetic screen provides further evidence that the physiological ligand of G6b-B is negatively charged HS, corroborating our in vitro binding data.

![The heparan sulfate biosynthesis pathway is required for G6b-B binding to HEK293 cells.\
(**A**) Recombinant G6b-B, produced as a monomeric biotinylated protein and conjugated to streptavidin-PE to generate an avid probe, binds to HEL, HEK293 and COLO-320-HSR cells. (**B**) A genome-wide loss-of-function approach identifies the HS biosynthesis pathway as the factor required to mediate the binding of recombinant G6b-B to HEK293 cells (left panel). X- and y-axis represent the log-fold-change (LFC) and robust rank aggregation (RRA) score calculated using the MAGeCK software, respectively. Circles represent individual genes and sizes represent the false-discovery rate (FDR): large circle = FDR \< 1%, small circle = 1% \< FDR \< 5%. Genes with FDR \< 5% are color coded according to their functional annotation and genes corresponding to the HS biosynthesis pathway are additionally named. The HS biosynthesis pathway is depicted in the right panel with the genes identified in the loss-of-function approach highlighted. Similar results were obtained in HEL cells (not shown). (**C**) G6b-B binding to HEK293 cells was measured by flow cytometry in the presence or absence of the indicated concentration of heparin or chondroitin sulfate. One representative out of three experiments is shown. (**D**) G6b-B loses its binding to cell lines when *SLC35B2*, encoding a transporter required for the sulfation of glycosaminoglycans (GAGs), is targeted. To ensure that the KO cells lack GAGs, a known HS binding protein, FGFRL1, is used as a control that confirms the loss of binding on these cell lines. Source data for the genomic screens in HEK293 and HEL cells are available in [Figure 3---source data files 1](#fig3sdata1){ref-type="supplementary-material"}--[2](#fig3sdata2){ref-type="supplementary-material"} and [3](#fig3sdata3){ref-type="supplementary-material"}--[4](#fig3sdata4){ref-type="supplementary-material"}, respectively.\
10.7554/eLife.46840.014Figure 3---source data 1.Raw read counts from the screen carried out in HEK293 cells.\
10.7554/eLife.46840.015Figure 3---source data 2.MAGeCK output for gene-wise ranking from the screen carried out in HEK293 cells.\
10.7554/eLife.46840.016Figure 3---source data 3.Raw read counts from the screen carried out in HEL cells.\
10.7554/eLife.46840.017Figure 3---source data 4.MAGeCK output for gene-wise ranking from the screen carried out in HEL cells.](elife-46840-fig3){#fig3}

Molecular basis of G6b-B interaction with the HS side-chains of perlecan {#s2-2}
------------------------------------------------------------------------

The extracellular domain of G6b-B is enriched in positively charged residues, especially arginines (12 in 125 amino acids; 9.6% vs 5.6% average frequency in mammalian membrane proteins \[[@bib28]\]), which are known to mediate strong binding to heparin ([@bib47]). Prior to obtaining the crystal structure, we generated a structural model of G6b-B using template-based tertiary structure prediction (RaptorX Structure Prediction server) and used this model to aid in the identification of candidate residues for mutagenesis. Examination of the model showed four basic residues (Lys54, Lys58, Arg60 and Arg61) in close spatial proximity to each other on a solvent-exposed loop. We tested whether these amino acids are involved in heparin binding by generating a mutant G6b-B (K54D, K58D, R60E, R61E; [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}) and by comparing heparin binding to WT G6b-B in transiently transfected CHO cells. An anti-G6b-B monoclonal antibody demonstrated a robust cell surface expression of mutant G6b-B that was comparable to that of WT G6b-B, suggesting that the quadruple mutation did not disrupt protein folding or expression ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). Cells expressing WT G6b-B showed an increase in heparin binding compared to that in non-transfected cells, whereas the cells expressing mutant G6b-B showed impaired binding when compared to WT G6b-B expressing cells, demonstrating that these amino acids (or a subset thereof) are involved in ligand binding ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}).

The crystal structure of the G6b-B extracellular domain (ECD)--dp12--Fab complex {#s2-3}
--------------------------------------------------------------------------------

Subsequent to the tertiary structure prediction, we were able to generate crystals of the ternary complex of the ectodomain of G6b-B bound to the heparin oligosaccharide dp12, scaffolded by a G6b-B-specific Fab fragment, and we determined the structure of this complex by X-ray crystallography to 3.1 Å resolution ([Figure 4](#fig4){ref-type="fig"} and [Table 2](#table2){ref-type="table"}). The construct that was used was N32D, S67A, S68A, S69A, T71A. The N32D mutation was made to remove the single potential N-linked glycosylation site. Intact mass spectrometry also revealed that after having made the N32D mutation, the measured mass of the protein was 948 Da greater than expected, consistent with O-glycosylation. Subsequent analysis identified five Ser and Thr residues as O-glycosylation sites, of which four were mutated to Ala in successful crystallization experiments.

![Ribbon representation of the ternary complex of the extracellular domain (ECD) of human G6b-B bound to heparin and the Fab fragment of a G6b-B-specific antibody.\
(**A**) Overview of the structure, with G6b-B colored in magenta and dark green, heparin shown as spheres, and the Fab fragment chains in light green/light blue, respectively. The assembly represents the asymmetric unit of the crystal lattice (space group *C*2). (**B**) Close-up view illustrating the position of the heparin ligand relative to the secondary structure of the G6b-B dimer. Heparin residues (shown as sticks) are sulfated D-glucosamine (SGN) and L-iduronic acid (IDS). The color coding of heparin atoms is: C, yellow; O, red; N, blue; and S, green. β-strands in G6b-B are labeled according to the canonical Ig-fold. (**C**) Superposition of chains F (various colors) and E (gray) of the G6b-B ECD. Strands are labeled according to the canonical β-sandwich topology of the variable Ig domain. The fold of G6b-B deviates from the canonical Ig fold in missing strand C′′, and as strand A is part of the β-sheet of strands B, E and D. Chain F is color ramped from blue (N-terminus) to red (C-terminus), and the position of the disulfide bond (Cys35--Cys108) is indicated by sticks in magenta. The glycosylation site Thr73 is shown (sticks) with glycosyl groups omitted from the view. (**D**) Multiple sequence alignment of G6b-B orthologs across mammalian species with secondary structure elements indicated above the sequence. Residue numbers refer to the sequence of human G6b. Conserved residues are boxed, with identities shown as white letters on a red background. Species abbreviations are: Hs, *Homo sapiens*; Pg, *Pan troglodytes* (chimpanzee); Mm, *Mus musculus* (mouse); Rn, *Rattus norvegicus* (rat); Oc, *Oryctolagus cuniculus* (rabbit); Cl, *Canis lupus familiaris* (dog); Sc, *Sos scroftus* (wild boar); and Bt, *Bos taurus* (cattle). G6b_mut is the sequence of the recombinant human G6b-B ECD used in crystallization, with mutations of the five putative glycosylation sites (marked with M). GY indicates the retained O-glycosylation site and DS indicates the disulfide cysteine residues.](elife-46840-fig4){#fig4}

10.7554/eLife.46840.022

###### Crystallographic data collection and refinement statistics for the G6b-B ECD--dp12--Fab complex.

  X-ray diffraction data                   
  ---------------------------------------- ---------------------------------
  Beamline                                 I03, Diamond Light Source
  Wavelength (Å)                           0.97624
  Space group                              *C*2
  Cell parameters (Å)                      183.8, 72.34, 131.0, β = 124.5°
  Complexes per asymmetric unit            1
  Resolution range (Å)                     65.27--3.13
  High resolution shell (Å)                3.18--3.13
  Rmerge (%)^\*^                           17.0 (146.6)
  Total observations, unique reflections   74,255/24,543
  I/σ(I)^\*^                               4.0 (0.7)
  Completeness (%)^\*^                     97.2 (98.2)
  Multiplicity^\*^                         3.0 (3.1)
  CC~1/2~^\*,\ †^                          0.991 (0.348)
  **Refinement**                           
  Resolution range                         63.1--3.13
  Unique reflections                       24,543
  R~cryst~, R~free~ (%)                    22.6, 26.0
  Number of non-H atoms                    7852
  RMSD bonds (Å)                           0.01
  RMSD angles (°)                          1.18
  B-factors                                
  Wilson (Å^2^)                            77.5
  Average overall (Å^2^)                   84.7
  RMSD B-factors (Å^2^)                    5.737
  Ramachandran statistics^‡^               
  Favored regions (%)                      91.2
  Allowed regions (%)                      8.3
  Disallowed (%)                           0.5

^\*^ parentheses refer to the high resolution shell.

^†^ as defined in [@bib36].

^‡^ calculated using molprobity ([@bib81]).

The solved complex encompasses six protein subunits, a dimer of G6b-B and two Fab fragments. As expected for a Fab-scaffolded structure, crystal packing contacts occur predominantly between the Fab fragment subunits ([Figure 4---figure supplement 2A](#fig4s2){ref-type="fig"}), but sparse direct contacts between symmetry-related G6b-B subunits also occur ([Figure 4---figure supplement 2B](#fig4s2){ref-type="fig"}).

Confirming the fold of the predicted model, the ectodomain of G6b-B forms an immunoglobulin-like fold of a topology closely resembling the structure of a variable immunoglobulin (Ig) domain ([Figure 4C](#fig4){ref-type="fig"}) ([@bib8]). A disulfide bond between cysteine residues 35 and 108 (strands B and F, respectively) stabilizes the immunoglobulin (Ig) fold ([Figure 4C](#fig4){ref-type="fig"}). The backbone does not form the canonical strand C′′, and only a very short strand D. In a canonical Ig domain, strand A is part of the sheet formed by strands B--E--D, but in the case of G6b-B, it is part of the opposite sheet (strands C′--C--F--G). The two G6b-B subunits (peptide chains E and F in the coordinate set) superimpose closely relative to the core β-sandwich structure, but divert markedly from each other in the loop connecting strands C′ and D (residues 66 to 81; [Figure 4C](#fig4){ref-type="fig"}). This loop includes several putative O-glycosylation sites ([Figure 4D](#fig4){ref-type="fig"}), which were mutated to Ala to ensure homogenous glycosylation of the protein. However, the O-linked glycosylation site Thr73 was retained, and electron density shows the presence of three saccharides attached to Thr73 in both peptide chains ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). Although the electron density (resolution 3.1 Å) does not allow the unequivocal identification of the saccharides, the groups could be modeled as galactose, α-N-acetyl-D-galactosamine and O-sialic acid, respectively. These glycosyl groups are well separated from the heparin oligosaccharide.

The ectodomain of G6b-B assembles into an apparent dimer with a pseudo two-fold symmetry oriented perpendicular to the extended β-sheet that forms the heparin binding site ([Figure 4C](#fig4){ref-type="fig"}). Dimer formation of G6b-B is driven by the heparin ligand, as demonstrated by size exclusion chromatography ([Figure 5](#fig5){ref-type="fig"}). Although G6b ECD was eluted at approximately 12.9 kDa, matching the molecular weight of the monomeric protein, the addition of the heparin oligomer dp12 (3.6 kDa) resulted in a complex of around 30.8 kDa, corresponding to the weight of two G6b-B molecules and one dp12 molecule ([Figure 5](#fig5){ref-type="fig"}).

![Heparin induces G6b-B dimer formation.\
Size exclusion chromatography of G6b-B ECD. Protein was either analyzed immediately or incubated at 4°C for 1.5 hr in the presence of dp12 before analysis on a Superdex 75 10/300 GL column. Molecular weights were estimated using a calibration curve. Values of 30.8 kDa and 12.9 kDa were obtained for G6b-B ECD in the presence and absence of dp12 (approx. 3.6 kDa), respectively. Ribonuclease A (13.7 kDa) and carbonic anhydrase (29 kDa) are shown for comparison.](elife-46840-fig5){#fig5}

The interface between chains E and F buries approximately 800 Å^2^ of solvent accessible surface area. In line with the modest surface area buried between the two subunits, the interface analysis using the PISA software does not predict a stable complex ([@bib41]), consistent with the observation that ectodomain dimerization is induced by the heparin ligand. Non-covalent contacts between the two chains consist almost entirely of van der Waals (vdW) and hydrophobic interactions, with Trp65^F^ and Pro62^F^ positioned centrally in the interface, contacting Pro62^E^ and Arg61^E^, while Trp65^E^ forms vdW contacts with Val77^F^. There are very few H-bond interactions (Ser57^E^-Oγ -- Ala66^F^-O/Ala68^F^-N; Lys58^E^-Nζ -- Arg43^F^-O) across the interface, and notably the central β-sheet (strands C′--C--F--G--A) is not continuous in that it lacks main chain -- main chain hydrogen bonds between the C′ strands of opposing protomers ([Figure 4B](#fig4){ref-type="fig"}). Nevertheless, dimerization creates a deep cleft, into which the heparin ligand inserts ([Figure 6A](#fig6){ref-type="fig"}). Crystallization involved a dodeca-saccharide, of which eight residues are visible in the electron density map ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}), with the central residues 4 and 5 representing sulfated L-iduronic acid (IDS) and D-glucosamine (SGN), respectively. Although the ligand-binding cleft provides partial charge complementarity to the sulfate groups of the heparin ligand ([Figure 6A](#fig6){ref-type="fig"}), perhaps surprisingly, only one sulfate group (residue SGN5) forms ionic interactions with basic side-chains (SGN5-O2S -- Arg60^F^-Nε 3.3 Å, SGN5-O3S-- Lys109^F^-Nζ 3.2 Å, where the superscript refers to the chain ID; [Figure 6B,C](#fig6){ref-type="fig"}). The other eight polar contacts (within a distance cut-off of 4 Å) involving sulfate groups are with backbone amides (Arg60^E^, Glu113^E^, His112^E^; 2.8--3.3 Å) rather than side-chains, while nine residues, including Lys109^E^, form vdW interactions with the ligand ([Figure 6B,C](#fig6){ref-type="fig"}). There is exquisite shape complementarity between the heparin and the surface of the G6b-B dimer, even though the S-shaped ligand only partially fills the ligand-binding cleft.

![Electrostatic surface potential of the G6b-B ECD and representation of non-covalent contacts between heparin and G6b.\
(**A**) The G6b-B dimer is shown with a translucent surface colored according to electrostatic surface potential (calculated using CCP4mg). The heparin ligand is shown as a stick model and polar contacts are indicated by dashed lines in magenta. Selected residues are labeled with superscripts indicating the relevant G6b-B protein chain. (**B, C**) Representation of non-covalent contacts between heparin and the G6b dimer. (**B**) Residues of G6b-B forming non-covalent contacts with heparin. Polar contacts are indicated by dashed lines in magenta, van der Waals interactions are visualized by showing the relevant residues with their (transparent) molecular surface. Superscript capitals designate the G6b-B protein chain. (**C**) LigPlot representation of the heparin--G6b-B contacts, with van der Waals or hydrophobic interactions indicated by the bent comb symbol, and polar contacts shown as dashed lines with distance indicated in units of Å.](elife-46840-fig6){#fig6}

We next measured the binding affinities of G6b-B for the various ligands using surface plasmon resonance (SPR). The human G6b-B-Fc-His6 homodimer and the human G6b-B-Fc-His6/Fc-StreptagII heterodimer were used as dimeric and monomeric G6b-B molecules, respectively. It is important to note that SPR measures the overall avidity rather than the direct binding affinity of the interactions, factoring in the effects of the multivalent nature of both the receptor (bivalent dimeric form) and the ligands themselves. In the configuration with chip-immobilized G6b-B molecules, heparin bound to both monomeric and dimeric G6b-B with high affinity (low nanomolar range). Similar values were obtained for fractionated (9 kDa) HS and the 12 saccharide heparin oligomer dp12. The binding affinity of perlecan was 366-fold weaker than that of heparin, in the low micromolar range ([Table 3](#table3){ref-type="table"} and [Figure 7A](#fig7){ref-type="fig"}). The reverse configuration was also tested, in which ligands were biotinylated and immobilized on streptavidin chips. The binding avidity of dimeric G6b-B to perlecan, fractionated HS and heparin was comparable to that measured in the ligand-immobilized configuration ([Table 3](#table3){ref-type="table"} and [Figure 7A](#fig7){ref-type="fig"}). Interestingly, in the ligand-immobilized configuration, differences in the binding of monomeric and dimeric G6b-B were observed for both heparin and fractionated HS, with the binding of the monomer being approximately 100-fold weaker than that of the dimer ([Table 3](#table3){ref-type="table"} and [Figure 7B](#fig7){ref-type="fig"}). The apparent decrease in the potency of monomer in the ligand-immobilized configuration versus that in the G6b-B-immobilized configuration is likely to be the result of the ligands themselves being multi-site molecules that are able to bind several sites on the immobilized G6b-B protein surface. Even when the monomeric form of G6b-B is immobilized in the standard assay configuration, the ligands' size and avidity allows them to bind multiple immobilized monomers simultaneously. When the configuration is reversed and the monomeric G6b-B is passed over the flow cell, only a weaker one-to-one binding mode is observed. More efficient binding of the dimeric form in this assay configuration correlates with our crystallography data showing that ligand binding induces dimer formation.

![High-affinity interaction between G6b-B and its ligands.\
Representative traces of the surface plasmon resonance experiments, results of which are presented in [Table 3](#table3){ref-type="table"}. (**A**) Binding of the indicated compound to immobilized dimeric G6b-B in the standard configuration. (**B**) Results from the reversed configuration, depicting traces of dimeric and monomeric G6b-B binding to immobilized heparin.](elife-46840-fig7){#fig7}
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###### Surface plasmon resonance affinities.

  Immobilized G6b-B receptor (standard configuration)                                                      
  ----------------------------------------------------- --------- ------------------- -------------------- --------------------
  Heparin                                               Monomer   1.12 ± 0.39×10^6^   2.01 ± 0.54×10^−3^   2.00 ± 1.17×10^−9^
                                                        Dimer     0.60 ± 0.56×10^6^   3.16 ± 1.17×10^−3^   7.76 ± 5.30×10^−9^
  Fractionated HS                                       Monomer   1.33 ± 0.01×10^5^   9.99 ± 0.16×10^−4^   7.47 ± 0.17×10^−9^
                                                        Dimer     1.20 ± 0.08×10^5^   1.71 ± 1.11×10^−3^   14.0 ± 8.26×10^−9^
  Perlecan                                              Monomer   1.94 ± 1.72×10^2^   1.01 ± 0.37×10^−4^   7.32 ± 4.64×10^−7^
                                                        Dimer     5.79 ± 6.94×10^3^   2.28 ± 2.51×10^−3^   4.74 ± 1.34×10^−7^
  dp12                                                  Monomer   0.31 ± 0.27×10^6^   2.39 ± 1.79×10^−3^   8.12 ± 1.22×10^−9^
                                                        Dimer     2.50 ± 2.72×10^6^   4.60 ± 5.01×10^−3^   1.84 ± 0.01×10^−9^
  Immobilized ligand (reversed configuration)                                                              
  Ligand                                                G6b-B     K~on~               K~off~               K~D~ (M)
  Heparin                                               Monomer   1.30 ± 0.29×10^5^   8.85 ± 0.40×10^−2^   6.99 ± 1.25×10^−7^
                                                        Dimer     3.28 ± 0.53×10^5^   1.73 ± 0.04×10^−3^   5.33 ± 0.75×10^−9^
  Fractionated HS                                       Monomer   9.22 ± 2.67×10^3^   6.40 ± 0.33×10^−3^   7.31 ± 2.47×10^−7^
                                                        Dimer     3.76 ± 4.69×10^4^   4.58 ± 6.32×10^−4^   7.70 ± 7.21×10^-9^
  Perlecan                                              Monomer   6.73 ± 3.38×10^3^   1.28 ± 0.24×10^−3^   2.28 ± 1.51×10^−7^
                                                        Dimer     4.90 ± 2.16×10^4^   6.78 ± 2.57×10^−4^   1.41 ± 0.09×10^−8^

Values are means ± SD from two independent experiments.

Biological effects of perlecan, heparin and HS on platelets and MKs {#s2-4}
-------------------------------------------------------------------

Having established HS as ligand for G6b-B, we examined the effect of surface-bound ligand on platelet function, using an in vitro platelet adhesion assay, in which human platelets were incubated on different substrates and their adhesion was quantified colorimetrically. Platelets bound to fibrinogen, as expected, but failed to adhere to perlecan ([Figure 8A](#fig8){ref-type="fig"}). However, removal of the HS side-chains by heparinase III treatment resulted in robust adhesion to perlecan. This adhesion might be mediated by interaction of integrin α2β1 with the perlecan protein core ([@bib6]), but the contribution of other receptors cannot be excluded. Importantly, perlecan also inhibited the adhesion to fibrinogen and collagen when immobilized together with these substrates. Again, this anti-adhesive effect was abolished upon treatment with heparinase III ([Figure 8A](#fig8){ref-type="fig"}). These results suggest that the HS side-chains of perlecan negatively regulate platelet adhesion.

![Heparan sulfate removal of perlecan facilitates platelet adhesion.\
The indicated substrates were coated alone or in combination onto wells in 96-well plates (2.5 µg/ml collagen and 10 µg/ml for all other substrates) overnight. Where indicated, wells were treated with 5 mU/ml heparinase III. Platelets from (**A**) humans or (**B**) mice were allowed to adhere for 1 hr and adhesion was quantified colorimetrically with 4-nitrophenyl phosphate(pNPP). (**A**) Human, platelets; n = 4--5 individual donors from 3 to 4 independent experiments; P-values were calculated using one-way ANOVA with Sidak's post-hoc test. (**B**) Mouse platelets; n = 4 samples/condition/genotype from two independent experiments. Owing to severe thrombocytopenia, platelets from up to five mice were pooled for one KO sample. P-values for differences between WT and *Mpig6b^--/^*^--^mice were calculated using two-way ANOVA with Sidak's post-hoc test. (**C, D**) Adhesion of (**C**) human or (**D**) WT and *G6b^--/^*^--^platelets on fibrinogen and perlecan. (**i**) Mean surface area of individual platelets quantified by KNIME software analysis. In panel (**C**) (i) n = 5 donors from two independent experiments. P-values were calculated using one-way ANOVA with Sidak's post-hoc test. Total number of cells analyzed: fibrinogen, 1957; perlecan, 239; perlecan + heparinase III, 686. In panel (**D**) (i) n = 5--7 mice/condition/genotype from 2 to 3 independent experiments. P-values were calculated using two-way ANOVA with Sidak's post-hoc test. Total number of cells analyzed: 134--176 for perlecan conditions, and 913--1277 for fibrinogen conditions. \*, p\<0.05; \*\*, p\<0.01; and \*\*\*, p\<0.001. (**ii**) Representative images of platelets stained for actin with phalloidin-Alexa-488; scale bar: 5 µm; hep III, heparinase III.](elife-46840-fig8){#fig8}

To determine whether this inhibitory effect of perlecan on platelet adhesion is mediated via G6b-B, we performed platelet adhesion experiments with platelets from WT and G6b-B knockout (*Mpig6b^--/^*^--^) mice ([Figure 8B](#fig8){ref-type="fig"}). WT mouse platelets exhibited adhesion characteristics that were similar to those of human platelets, with the exception that they adhered weakly to heparinase III-treated perlecan ([Figure 8B](#fig8){ref-type="fig"}). Importantly, co-coating of fibrinogen together with perlecan reduced the adhesion of WT but not of G6b^--/--^platelets, resulting in enhanced adhesion of *Mpig6b^--/^*^--^platelets under this condition. Pre-treatment of perlecan with heparinase III abolished this difference ([Figure 8B](#fig8){ref-type="fig"}). Adhesion of WT platelets to collagen was inhibited by perlecan in a similar manner as human platelets (data not shown). Platelets from *Mpig6b^--/^*^--^could not be meaningfully evaluated on collagen, because of the severe reduction in GPVI surface expression ([@bib50]). Collectively, these findings demonstrate that the G6b-B--HS interaction inhibited the adhesion of human platelets to the perlecan protein core, collagen and fibrinogen, suggesting an inhibitory effect on integrin and GPVI signaling.

We next investigated the morphological changes in platelets that are adherent to perlecan by microscopy. In contrast to human platelets adhering to fibrinogen, which exhibited characteristic spreading and actin stress fiber formation, platelets adhering to perlecan were small in size and did not spread. The removal of the HS chains of perlecan resulted in a modest increase in size, although the platelets were still much smaller than the platelets adhering to fibrinogen alone ([Figure 8C](#fig8){ref-type="fig"}).

Mouse WT platelets, like human platelets, did not spread on perlecan and were small ([Figure 8D](#fig8){ref-type="fig"}), although platelets from *Mpig6b^--/^*^--^mice spread to a greater extent, indicating their activation. This was not simply due to the larger size of the *Mpig6b^--/^*^--^platelets, as they did not differ in size from WT platelets when spread on fibrinogen, in line with previous findings ([@bib50]). Moreover, this size difference was abolished upon heparinase III treatment of perlecan, demonstrating that HS also has an activating effect on platelets, presumably through an activation receptor that is inhibited by G6b-B. Of note, platelets from *Mpig6b^diY/F^* mice, which express physiological levels of a signaling-incompetent G6b-B, recapitulated the enhanced spreading phenotype of *Mpig6b* KO platelets (data not shown). Hence, we conclude that G6b-B signaling is required to inhibit platelet activation in the presence of HS.

We next investigated the potential effect of perlecan on MKs. Staining of WT mouse bone marrow sections revealed perlecan expression in vessel walls, which co-localized with the sinusoid marker endoglin (CD105) ([Figure 9A](#fig9){ref-type="fig"} and [Figure 9---figure supplement 1](#fig9s1){ref-type="fig"}). This raised the possibility that MK G6b-B is likely to come into direct contact with the HS chains of perlecan in sinusoidal vessels during MK maturation and proplatelet formation. The same observation was made in the bone marrow of G6b-B-deficient animals ([Figure 9A](#fig9){ref-type="fig"}). Consistent with previous findings ([@bib50]), however, we observed an increased number of MKs in *Mpig6b^--/^*^--^animals ([Figure 9B](#fig9){ref-type="fig"}), distributed throughout the bone marrow as atypical clusters ([Figure 9C](#fig9){ref-type="fig"} and [Figure 9---figure supplement 2](#fig9s2){ref-type="fig"}). Despite the increase in the number of MKs, *Mpig6b^--/^*^--^mice showed similar frequencies of the different maturation stages of MKs, as quantified by EM ([Figure 9D,E](#fig9){ref-type="fig"}), arguing against an overall defect of MK maturation in *Mpig6b^--/^*^--^mice.

![Megakaryocytes come into contact with perlecan in the bone marrow.\
(**A**) Analysis of immunofluorescent images of murine femur sections from WT and *Mpig6b^--/^*^--^mice. Sinusoids were marked using anti-endoglin (CD105) and MKs by anti-GPIX antibodies. Perlecan is abundantly expressed within the bone marrow cavity, present in intersinusoidal spaces and part of basement membranes in sinusoids and arterioles. MKs come into contact with perlecan. Scale bar: 20 µm. (**B**) Quantification of MKs in the bone marrow of WT and *Mpig6b^--/^*^--^mice; three animals of each genotype with five images per animal were analyzed. (**C**) Analysis of MK clustering, with % of clustered MKs per visual field with a total number of three mice per genotype analyzed; P values were calculated with Mann-Whitney U-test \*\*, p\<0.01. (**D**) Classification of the MK according to their maturation stage: stage I (absence of granules), stage II (granules and developing demarcation membrane system (DMS) not yet organized), stage III (DMS organized in cytoplasmic territories). Data are reported as the percentage of the total number of MK. Bars represent the mean ± SEM in three bone marrow samples (total number of MK counted 395--469). (**E**) Representative transmission electron microscopy (TEM) images of bone marrow from WT and *Mpig6b^−/−^* mice. Bars: 10 µm.](elife-46840-fig9){#fig9}

To investigate the impact of the G6b-B interaction with HS on MKs, we analyzed the spreading and adhesion of bone marrow-derived MKs on different surfaces in vitro ([Figure 10](#fig10){ref-type="fig"}). We found that only very few WT and *Mpig6b^--/^*^--^MKs adhered to a perlecan-coated surface ([Figure 10](#fig10){ref-type="fig"}). Whilst perlecan-adherent WT MKs were small in size, *Mpig6b^--/^*^--^MKs spread to a greater degree on the same substrate. The same effect was observed when perlecan was co-immobilized with fibrinogen, and heparinase III treatment abolished the difference ([Figure 10](#fig10){ref-type="fig"}). Hence, similar to platelets, exposure of MKs to HS resulted in increased size in the absence of G6b-B, confirming the inhibitory function of this receptor.

![G6b knockout megakaryocytes show enhanced spreading on perlecan.\
Adhesion of WT and *Mpig6b^--/^*^--^MKs on perlecan. (**i**) Mean surface area of MKs was quantified with ImageJ. n = 4--6 mice/condition/genotype from three independent experiments; total cell numbers analyzed per condition/genotype were 77--188 for conditions with perlecan only and 1671--2866 for conditions with fibrinogen. P values were calculated using two-way ANOVA with Sidak's post-hoc test, \*\*\*, p\<0.001; \*, p\<0.05. (ii) Representative images of platelets stained for tubulin (green) and DAPI (blue); scale bar: 20 µm.](elife-46840-fig10){#fig10}

We next investigated the biological effects of G6b-B ligands on platelet aggregation in response to collagen, which activates platelets via the ITAM-containing receptor complex GPVI-FcR γ-chain ([@bib61]). Heparin and HS both enhanced platelet aggregation in response to subthreshold concentrations of collagen ([Figure 11](#fig11){ref-type="fig"}). This is in line with previous reports and may be explained by binding of these ligands to multiple platelet receptors ([@bib27]; [@bib66]; [@bib68]), resulting in an overall aggregation-promoting response. We did not find an effect of perlecan on collagen-mediated platelet aggregation at the concentrations tested, suggesting that perlecan must be immobilized to surface in order to provide HS chains at a sufficient density to observe the inhibitory effects observed in adhesion experiments ([Figures 8](#fig8){ref-type="fig"} and [9](#fig9){ref-type="fig"}). In addition, multiple direct and indirect effects on platelets through the perlecan protein core, as described previously ([@bib6]), may mask an effect of the HS chains in this assay.

![Effects of G6b-B ligands on platelet aggregation.\
Human platelet rich plasma (PRP) was incubated with the indicated compound for 90 s prior to agonist addition. Aggregation traces were recorded on a Chronolog four channel aggregometer. Averaged aggregation traces (left) and area under the curve (AUC) quantification (right) of platelet aggregation (n = 3--5 per condition). P-values were calculated using one-way ANOVA with Dunnett's post-hoc test and refer to the untreated control. \*\*\*, p\<0.001; \*\*, p\<0.01; and \*, p\<0.05.](elife-46840-fig11){#fig11}

To overcome this limitation, we took advantage of the multivalent semisynthetic heparin proteoglycan mimetic APAC ([@bib43]; [@bib42]) in this assay. APAC consists of unfractionated heparin covalently coupled to a human albumin core, providing a high local density of heparin molecules. In contrast to single-chain heparin, APAC dose-dependently inhibited collagen-induced platelet aggregation ([Figure 11](#fig11){ref-type="fig"}), with an almost complete block observed at 0.5 µM, as previously described ([@bib43]).

We next examined the effect of heparin and APAC on WT and G6b-B deficient platelets using a flow-cytometric approach, sufficing much smaller sample volumes than aggregation assays, using integrin αIIbβ3 activation (fibrinogen-A488 binding) and degranulation-dependent TLT-1 surface exposure ([@bib75]) as markers for platelet activation. APAC and heparin had no detectable effect on WT platelets, but APAC induced robust integrin activation and platelet secretion in G6b-B deficient platelets, demonstrating a platelet-activating effect of this compound in the absence of G6b-B ([Figure 12A](#fig12){ref-type="fig"}). Next, we aimed to investigate the impact of G6b-B ligands on ITAM-mediated platelet activation in WT and *Mpig6b* KO mice. Owing to severe reduction of GPVI receptor levels in G6b-B deficient animals, we stimulated platelets with an antibody directed against the hemi-ITAM receptor CLEC-2, expression of which is not affected by G6b-B deficiency ([@bib50]). APAC, but not heparin, significantly inhibited platelet degranulation and fibrinogen binding in response to CLEC-2 stimulation in WT platelets. Importantly, this inhibitory effect of APAC on degranulation was not observed in platelets from G6b-B-deficient animals ([Figure 12B](#fig12){ref-type="fig"}). Fibrinogen binding was also significantly reduced by APAC in G6b-B-deficient mice, but to a lesser extent than in WT platelets ([Figure 12B](#fig12){ref-type="fig"}). The inhibitory effect of APAC was also absent in the platelets from *Mpig6b^diY/F^* mice, which express a signaling-incompetent form of G6b-B ([Figure 12C](#fig12){ref-type="fig"}). Hence, we conclude that APAC suppresses CLEC-2-mediated platelet activation via G6b-B by recruiting the downstream phosphates Shp1 and Shp2. Overall, these findings demonstrate that multivalent G6b-B ligands inhibit platelet activation via (hemi)ITAM receptors, whereas soluble single-chain molecules do not.

![APAC inhibits CLEC-2-mediated degranulation in WT but not *Mpig6b* KO platelets.\
Mouse blood, diluted 1:10 in Tyrode's buffer was incubated with the indicated compounds (0.05 µM) in the (**A**) absence or (**B**) presence of a stimulating CLEC-2 (3 µg/ml) for the indicated time. Samples were fixed and TLT-1 surface levels, a marker for platelet degranulation or fibrinogen-Alexa488 binding (a measure of integrin activation), were determined by flow cytometry. n = 5--6 mice/condition/genotype from two independent experiments. P-values were calculated using (**A**) two-way ANOVA with Sidak's post-hoc test (comparison of WT APAC vs *Mpig6b^--/^*^--^ APAC) or (**B**) two-way ANOVA with Tukey's post-hoc test, and refer to the difference between WT and *Mpig6b^--/--^.* \*\*\*, p\<0.001; \*\*, p\<0.01; and \*, p\<0.05. (**C**) Mouse blood was incubated with the indicated compounds for 20 min. Samples were fixed and TLT-1 surface levels were determined by flow cytometry. n = 6--8 mice/condition/genotype from three independent experiments. P-values were calculated using two-way ANOVA with Tukey's post-hoc test. \*\*\*, p\<0.001; and \*\*p\<0.01. Source data are available in [Figure 12---source data 1](#fig12sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.46840.036Figure 12---source data 1.Source data for graphs shown in [Figure 12A--C](#fig12){ref-type="fig"}.](elife-46840-fig12){#fig12}

Conjugated heparin induces the phosphorylation of G6b-B and downstream signaling {#s2-5}
--------------------------------------------------------------------------------

We performed signaling studies to gain mechanistic insights into the opposing effects of soluble heparin vs. conjugated heparin. Washed human platelets were incubated with heparin or APAC, and their lysates were immunoblotted with an anti-phospho-tyrosine antibody (p-Tyr). Both heparin or APAC induced moderate changes in whole-cell tyrosine phosphorylation as compared to collagen, with APAC having a stronger effect ([Figure 13A](#fig13){ref-type="fig"}). The most pronounced change observed in response to G6b-B ligation was an increase in the signal intensity of a 150 kDa protein, as well as of a doublet in the heparin- and APAC-treated sample migrating at 27 and 32 kDa, which correlated with glycosylated and non-glycosylated human G6b-B. Hence, we assessed the phosphorylation status of G6b-B using custom phospho-tyrosine-specific G6b-B antibodies directed against phosphorylated ITIM and ITSM of G6b-B ([Figure 13A](#fig13){ref-type="fig"}), and by immunoprecipitating the receptor and blotting with the p-Tyr antibody ([Figure 13---figure supplement 1A](#fig13s1){ref-type="fig"}). Heparin, and to a greater extent APAC, enhanced the basal phosphorylation of G6b-B, which was accompanied by an increase in Shp1 and Shp2 association ([Figure 13A](#fig13){ref-type="fig"} and [Figure 13---figure supplement 1](#fig13s1){ref-type="fig"}). Similar results were obtained with HS, but to a lesser extent than with either heparin or APAC ([Figure 13---figure supplement 1B](#fig13s1){ref-type="fig"}). Perlecan did not induce the phosphorylation of G6b-B, in line with our observation in the aggregation assay, suggesting perlecan must be surface-immobilized to have an effect on platelets ([Figure 13---figure supplement 1A](#fig13s1){ref-type="fig"}).

![APAC induces G6b-B phosphorylation and downstream signaling.\
(**A**) Washed human platelets (5 × 10^8^/ml) were incubated for 90 s with 0.05 µM APAC, 0.7 µM heparin or buffer in the presence of 10 µM integrilin. Where indicated, platelets were additionally stimulated with 3 µg/ml collagen for 90 s following compound treatment. Samples were lysed and whole cell lysates (WCL) were analyzed by western blotting. Representative western blots are from n = 3--5 independent experiments. (**B**) Lysates were also analyzed by quantitative capillary-based gel electrophoresis with the indicated antibodies. Representative data are displayed as blots on the left and as quantified peak areas on the right. (**C, D**) Washed mouse platelets (5 × 10^8^/ml) were incubated for 90 s with 0.05 µM APAC or buffer in the presence of 10 µM lotrafiban. Samples were analyzed as described above. The *Mpig6b^--/^*^--^samples show IgG light chain fragments, which result from IgG binding to the platelet surface. P-values were calculated using one-way ANOVA with Sidak's post-hoc test. \*\*\*, p\<0.001; \*\*, p\<0.01; and \*, p\<0.05. p-Tyr, anti-phosphotyrosine (4G10).](elife-46840-fig13){#fig13}

Using a quantitative capillary-based gel electrophoresis platform (ProteinSimple Wes), we investigated the effects of heparin and APAC on the phosphorylation status of the tyrosine phosphatases Shp1 (pTyr562) and Shp2 (p-Tyr580 and p-Tyr542), which are essential effectors of G6b-B signaling ([@bib29]). Strikingly, APAC induced prominent phosphorylation of Shp1 and Shp2, whereas heparin only induced modest changes in Shp2 phosphorylation ([Figure 13B](#fig13){ref-type="fig"}). We also observed a marginal increase in SFK phosphorylation (p-Tyr418) in platelets treated with heparin and APAC, correlating with increased phosphorylation of G6b-B under these conditions ([Figure 13B](#fig13){ref-type="fig"}).

Subsequently, we compared the effects of heparin and APAC on GPVI signaling in response to an intermediate concentration of collagen (3 µg/ml). Although both compounds further enhancing collagen-induced phosphorylation of G6b-B, and although APAC also enhances the phosphorylation of Shp phosphatases ([Figure 13B](#fig13){ref-type="fig"}), whole-cell phosphorylation remained largely unaltered ([Figure 13A](#fig13){ref-type="fig"}). Similarly, we also found no inhibitory effect of heparin or APAC on Src (p-Tyr418) and Syk (p-Tyr525/6) phosphorylation, both critical kinases for initiating and propagating GPVI signaling ([@bib73]) ([Figure 13B](#fig13){ref-type="fig"}).

To corroborate that the APAC-induced increase in Shp1 and Shp2 phosphorylation are mediated by G6b-B, we conducted signaling experiments in platelets from WT and *Mpig6b^--/^*^--^mice. APAC treatment of WT platelets recapitulated the effects observed in human platelets, showing only a modest change in overall phosphorylation pattern, and an increase in Shp1 and Shp2 phosphorylation ([Figure 13C,D](#fig13){ref-type="fig"}). By contrast, APAC-induced robust tyrosine phosphorylation in G6b-B-deficient platelets ([Figure 13C](#fig13){ref-type="fig"}), indicative of reduced inhibitory signaling and platelet hyperreactivity the absence of G6b-B. Strikingly, this was accompanied by reduced tyrosine phosphorylation of Shp1 and Shp2 in these platelets compared with WT platelets ([Figure 13D](#fig13){ref-type="fig"}). Collectively, these findings demonstrate that heparin and APAC have a direct effect on G6b-B phosphorylation, however, only the high-density ligand APAC is able to induce robust downstream inhibitory signaling via G6b-B, culminating in Shp1 and Shp2 binding and tyrosine phosphorylation.

Discussion {#s3}
==========

In this study, we present evidence that establishes G6b-B as a functional receptor of HS and heparin. Little was known about the effects of GAGs on platelet and megakaryocyte function and the underlying molecular mechanisms, thus these findings represent a major advance in our understanding of the interaction, and of the biological and biochemical effects, of GAGs on these cells. Using a mass-spectrometry-based approach and subsequent in vitro binding assays, we identified the HS chains of perlecan as a physiological binding partner of G6b-B. The binding of G6b-B to HS was corroborated by a cell-based CRISPR KO screening, which identified molecules involved in the HS synthesis pathway as a prerequisite of G6b-B binding. There are two possible explanations as to why this assay did not identify perlecan, nor any other individual HSPGs as binding partners of G6b-B: first, the CRISPR screening approach will not identify genes that are essential for cell viability; and second, it will not identify proteins that have redundant functions. Given that perlecan is secreted from endothelial and smooth muscle cells, it is possible that there could be HSPGs other than perlecan (syndecans/glypicans) on the cell surface that carry the GAG chains in HEK cells. As the molecules in the HS synthesis pathway are essential for their respective synthesis, they can be identified in this approach more easily. This potential redundancy of HSPGs may also exist in vivo, and we cannot exclude the possibility that G6b-B may interact with other HSPGs in the cardiovascular system.

As with many other HS-binding molecules, G6b-B also binds structurally related heparin ([@bib82]). Indeed, the interaction between heparin and G6b-B had been described previously, but the molecular details of the interaction and their functional significance had not been determined ([@bib18]). HS chains are not homogenously sulfated; instead, highly sulfated residues are clustered in domains along the polymer (called N-sulfated (NS) or sulfated (S) domains), which are interspersed by stretches of N-acetylated disaccharides (NA domains) that are largely devoid of sulfate groups ([@bib57]; [@bib82]). Heparin, a degradation product derived from HS isolated from porcine intestine, shows larger NS domains and a greater degree of sulfation than HS. Hence, it is often used as an analogue for the NS domains of HS, despite the limitation that it may lack the protein binding properties of less sulfated HS. Our structural analysis of the G6b-B ligand complex shows that G6b-B interacts with multiple sulfates in the heparin oligosaccharide. Hence several observations, including the higher potency of heparin in inducing G6b-B phosphorylation as compared to HS, and the shift in dose-response curve in aggregometry, may be due to the larger NS domains in the heparin molecule. In addition, synthesis of HS is not template-driven, therefore, the length and distribution of such domains is regulated in a tissue- or cell-specific manner, adding additional complexity to the regulatory role of HS.

Our size-exclusion chromatography data demonstrate that the dimerization of G6b-B is induced by the heparin ligand. The crystal structure of heparin-bound G6b-B reveals the mode of ligand binding and how the binding of this ligand induces ectodomain dimerization. The contact surfaces between the G6b-B dimer and the Fab fragments are spatially separated from the heparin-binding site, suggesting that the presence of the Fab fragments does not interfere with heparin binding. Heparin-dependent, non-constitutive dimerization of G6b-B is consistent with the small interface between the G6b-B subunits and the absence of main chain-main chain hydrogen bonds across the β-sheet of the binding surface. Among 34 entries currently in the PDB of structures containing heparin as a ligand, dimeric assemblies (or multimeric assemblies with a two-fold rotation axis) are common ([Figure 14---figure supplement 1](#fig14s1){ref-type="fig"}), but the anti-parallel alignment of two Ig-like domains in the heparin-bound structure of G6b-B appears to be unique ([@bib11]; [@bib16]; [@bib26]; [@bib65]; [@bib69]). The involvement of the β-sheet surface in heparin binding is somewhat reminiscent of how carbohydrate-binding modules (CBM) bind saccharide ligands ([@bib1]). CBMs are non-enzymatic domains often associated with carbohydrate-active enzymes, which contribute to carbohydrate binding and discrimination ([@bib7]).

The crystal structure of G6b-B shows a prominent positively charged electrostatic surface area, but this positive surface patch runs perpendicular to the central cleft of the G6b-B dimer. Indeed, the heparin oligosaccharide lines up with the cleft, rather than extending along the positive surface patch. Comparison with other heparin-bound structures ([Figure 14---figure supplement 1](#fig14s1){ref-type="fig"}) suggests that charge complementation is not the sole determinant of the mode of heparin binding, and that the depth and shape of the docking site are likely to be important as well. Nevertheless, charge complementing ionic interactions lock the ligand in to register at the center of the G6b-B binding cleft, where the sparsity of sulfate-Arg or sulfate-Lys interactions is surprising. The crystal structure rationalizes the diminished binding of G6b-B transfected HEK293 cells to biotinylated heparin when the four basic residues Lys54, Lys58, Arg60 and Arg61 are simultaneously mutated. Among these four side-chains, the key interaction appears to be with Arg60, as Arg61 is shielded through G6b-B dimerization from the ligand, Lys54 is well separated from the binding cleft and Lys58 is situated within a 4 Å-radius of heparin, but makes no polar interactions. The heparin ligand does not exhaust the possibilities for specificity-determining interactions with G6b-B in the ligand-binding cleft. For instance, Arg60^F^ and Lys109^F^, but not their counterparts in chain E on the opposite side of the cleft, are involved in ionic interactions with the same sulfate group. It is conceivable that the physiological HS ligand of G6b-B may have a different pattern of sulfate groups that engage both Arg60 and Lys109, perhaps in addition to Lys58.

Since G6b-B shows a considerable degree of glycosylation, the question arises as to whether this might modulate the ligand interaction. Through the course of our structural analysis of G6b-B, we identified multiple glycosylation sites (N32, S67, S68, S69, T71, T73) in the G6b-B ectodomain. Although most of these sites can be mutated to increase protein homogeneity for crystallization studies, the final structure of the G6b-B--heparin complex revealed that all of these glycosylation sites are spatially separated from the ligand-binding surface, and are not likely to impede ligand binding sterically. All of the recombinant G6b-B molecules used in this study were produced in mammalian cell lines and are therefore glycosylated. We previously showed that MK and platelet G6b-B migrate at the same molecular weight by Western blotting ([@bib50]), suggesting that G6b-B is not differentially glycosylated in MKs and platelets. We currently have no evidence that the glycosylation of G6b-B alters ligand binding.

Investigating the functional consequences of this interaction revealed that heparin and HS have complex effects on platelet function and that G6b-B is a key regulator in this process. Our data demonstrates that, to induce robust inhibitory biological or signaling effects, G6b-B ligands need to be either immobilized to a surface, as in the case of perlecan-coated plates, or multivalent, as in the case of APAC. By contrast, single-chain heparin and HS enhanced rather than inhibited platelet aggregation. These findings are in line with numerous previous reports, showing enhancing effects of heparin on platelet aggregation in platelet-rich plasma ([@bib27]; [@bib66]; [@bib68]). This most likely also contributes to a mild drop in platelet counts in patients receiving heparin, referred to as non-immune heparin-induced thrombocytopenia ([@bib14]). On the basis of our signaling data and size-exclusion chromatography data, we assume that heparin, despite being able to dimerize the receptor, fails to cluster G6b-B sufficiently into higher-order oligomers to induce robust downstream signaling ([Figure 14A,B](#fig14){ref-type="fig"}). It remains to be determined whether the enhancing effects of heparin and HS on platelet aggregation is mediated by reducing the inhibitory effects of G6b-B alone or by additional effects on other platelet receptors, which promote platelet activation, such as the integrin αIIbβ3, previously shown to bind heparin ([@bib25]; [@bib27]; [@bib76]).

![Simplified model of glycan-mediated regulation of G6b-B function.\
(**A**) In the absence of any ligand, G6b-B is mainly present in a monomeric state and phosphorylated to a low degree. (**B**) Small soluble ligands, for example heparin, induce the dimerization of the receptor, but induce only mild G6b-B phosphorylation and downstream signaling. (**C**) Multivalent ligands, for example the HS chains of vessel-wall perlecan (not shown) or the heparin molecules in APAC, cluster G6b-B dimers into higher-order oligomers. Hence, they facilitate downstream signaling of G6b-B, including robust phosphorylation of G6b-B and downstream Shp1 and Shp2 phosphatases, resulting in the inhibition of platelet activation. SFK, src family kinase.](elife-46840-fig14){#fig14}

In contrast to these soluble, monovalent ligands, the HS side-chains of immobilized perlecan exerted an inhibitory effect on platelets, as evidenced by the impaired adhesion of platelets to collagen and fibrinogen. This extends observations from previous reports describing the anti-adhesive properties of the HS chains of perlecan, although the underlying mechanism was not known ([@bib40]; [@bib46]). Moreover, heparinized polymers showed less platelet adhesion than their non-heparinized counterparts ([@bib30]; [@bib45]; [@bib63]). Our results with platelets from G6b-B-deficient mice demonstrate that heparin or HS engagement by G6b-B on these surfaces induces an inhibitory signal, blocking platelet activation and adhesion.

The failure of perlecan to have an effect on collagen-mediated platelet aggregation and platelet signaling in solution might simply be a consequence of the test conditions and suggests that it must be immobilized to a surface in order to present HS chains at a density sufficient to induce the inhibitory effects observed. Hence, to determine the effect of G6b-B clustering in solution, we took advantage of APAC, which mimics naturally occurring macromolecular heparin proteoglycans and harbors a higher GAG density than perlecan. On the basis of our findings, and given the dependence of G6b-B binding to sulfate groups and the common use of heparin as an analog for the NS domains of HS ([@bib82]), we concluded that the inhibitory effect of both APAC and the HS chains of perlecan is mediated by clustering G6b-B. We compared the effect of APAC to that of single-chain heparin, which differ only by the clustering of the chains, but not the structure or composition of the polysaccharide chains. Similar to previous reports ([@bib37]; [@bib43]; [@bib42]), we found that APAC inhibited platelet activation via the ITAM-containing GPVI-FcR γ-chain receptor complex, and also via the hemi-ITAM-containing receptor CLEC-2. Thus, by increasing the clustering capacity of heparin to a multivalent form, an inhibitory effect on platelet function was achieved in solution. In line with this observation, we found that APAC induced stronger phosphorylation of G6b-B, which was accompanied by the association and phosphorylation of the tyrosine phosphatases Shp1 and Shp2, which is not observed in G6b-B-deficient platelets. We therefore conclude that clustering of G6b-B receptor dimers into higher-order oligomers by an immobilized or multivalent ligand is required for the inhibitory effect on platelet function ([Figure 14C](#fig14){ref-type="fig"}).

Perlecan is secreted by endothelial and smooth muscle cells into the extracellular space of the vessel wall and hence is inaccessible by platelet G6b-B in an intact blood vessel ([@bib56]; [@bib67]; [@bib70]). Only upon vascular injury will the interaction between platelet G6b-B and perlecan occur, resembling the interaction of other platelet receptors with ligands that are expressed in the vessel wall, including collagen, laminin and fibronectin ([@bib4]). Given the results of our adhesion assay, we speculate that the interaction of platelet G6b-B with perlecan negatively regulates the initial steps of thrombus formation, preventing thrombi from forming unnecessarily.

The G6b-B-HS interaction may also be relevant for triggering the directional formation of proplatelets by MKs towards sinusoidal blood vessels at sites of platelet production. A key, yet unresolved, question is how MKs remain relatively refractory and do not release platelets into the ECM-rich environment of the bone marrow despite expressing the same repertoire of cell-surface receptors as platelets. G6b-B is highly expressed in mature MKs and G6b-B KO and loss-of-function mice show a severe macrothrombocytopenia resulting from impaired proplatelet formation and platelet production, which is accompanied by an increase in MK numbers in the bone marrow ([@bib29]; [@bib50]). Here, we provide first evidence for a potential role of perlecan in regulating MK function by demonstrating that G6b-B-deficient, but not WT, MKs increase their size in the presence of the HS side-chains of perlecan, indicating cellular activation. Because it has been shown in vitro ([@bib50]) and ex vivo (this publication) that G6b-B-deficient MKs have no overt maturation defect and as an increase in size was only observed in the presence of the HS chains of perlecan, it seems unlikely that the increase in size results from an overall maturation defect of the MKs. In addition, findings from our study and others demonstrate that perlecan is abundantly expressed in the bone marrow ECM and comes into contact with mature MKs ([@bib24]). We hypothesize that the MK G6b-B-HS interaction might play a role in regulating polarized proplatelet formation in the sinusoidal blood vessel lumen.

Despite sharing a common structure, the biophysical details of HS are tissue- or cell-specific, including variability of sulfation patterns, suggesting that the regulatory role of HS occurs in a spatiotemporal manner in different tissues and at different developmental and pathological stages. Hence, future research is needed to investigate whether and to what extent G6b-B interacts with other HS proteoglycans and to determine the physiological relevance of these interactions under normal and pathological conditions, such as cardiovascular disease in which the composition of the vascular glycocalyx is altered ([@bib39]). Moreover, our results also demonstrate that platelets and MKs from G6b-B-deficient mice showed an activation response towards the HS chains of immobilized perlecan and, in case of platelets, also towards APAC, even in the absence of a classical platelet agonist such as collagen. Hence, one of the key functions of G6b-B in vivo may not be solely restricted to the inhibition of platelet function upon vascular injury, but may also retain platelets in a resting state by inhibiting other HS-binding platelet receptors, which remain to be identified. Notably, the HSPGs syndecan-1 and −4 are expressed on the surface of endothelial cells that form an integral part of the glycocalyx ([@bib48]). As platelets marginate to the vessel wall, the interaction of G6b-B on circulating platelets within the glycocalyx may induce a low level inhibitory signal that helps to maintain platelets in an inactive state, in line with the basal phosphorylation of G6b-B in resting platelets.

In summary, our findings establish the interaction of G6b-B with heparan sulfate as a novel mechanism regulating platelet reactivity, and demonstrate important implications of this interaction in the regulation of platelet production and the adverse effects upon soluble heparin administration.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                      Designation                                                               Source or\                                                       Identifiers                                                                               Additional\
  (species) or\                                                                                                reference                                                                                                                                                  information
  resource                                                                                                                                                                                                                                                                
  ---------------------------------- ------------------------------------------------------------------------- ---------------------------------------------------------------- ----------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------
  Genetic reagent (*Mus musculus*)   *Mpig6b^--/--^*                                                           PMID: [23112346](https://www.ncbi.nlm.nih.gov/pubmed/23112346)                                                                                             Dr. Yotis Senis (University of Birmingham and EFS Grand Est, Inserm UMR-S1255)

  Genetic reagent (*M. musculus*)    *Mpig6b^diYF/diYF^*                                                       PMID: [29891536](https://www.ncbi.nlm.nih.gov/pubmed/29891536)                                                                                             Dr. Yotis Senis (University of Birmingham and EFS Grand Est, Inserm UMR-S1255)

  Cell line (*Cricetulus griseus*)   A5 CHO                                                                    other                                                                                                                                                      provided by Dr. Ana Kasirer-Friede and Dr. Sanford Shattil (University of California, San Diego)

  Antibody                           anti-perlecan (rat monoclonal)                                            Santa Cruz Biotechnologies                                       clone A7L6; sc-33707; RRID:[AB_627714](https://scicrunch.org/resolver/AB_627714)          (1:100); used for IF staining of bone marrow (BM)

  Antibody                           anti-mouse CD105 (Endoglin) (rat monoclonal)                              eBioscience/Thermo Fisher Scientific                             \#MA5-17943; clone MJ7/18; RRID:[AB_2539327](https://scicrunch.org/resolver/AB_2539327)   (1:100); used for IF staining of BM

  Antibody                           anti-GPIX-Alexa488 (rat monoclonal)                                       other                                                            clone 56F8                                                                                1.4 µg/ml; used for IF staining of BM, custom made lab reagent

  Antibody                           anti rat IgG Alexa 647 (goat polyclonal)                                  Invitrogen                                                       \#A-21247; RRID:[AB_141778](https://scicrunch.org/resolver/AB_141778)                     (1:300); used for IF staining of BM

  Antibody                           anti rat IgG Alexa 546 (goat polyclonal)                                  Invitrogen                                                       \#A-11081; RRID:[AB_141738](https://scicrunch.org/resolver/AB_141738)                     (1:300); used for\
                                                                                                                                                                                                                                                                          IF staining of BM

  Antibody                           anti-actin (mouse monoclonal)                                             Sigma-Aldrich                                                    \#A4700, clone AC-40; RRID:[AB_476730](https://scicrunch.org/resolver/AB_476730)          (1:1000)

  Antibody                           Anti-α-tubulin (mouse monoclonal)                                         Sigma-Aldrich                                                    \#T6199, clone DM1A; RRID:[AB_477583](https://scicrunch.org/resolver/AB_477583)           (1:1000)

  Antibody                           anti-GAPDH (rabbit monoclonal)                                            Cell Signaling Technology                                        \#2118, clone: 14C10; RRID:[AB_561053](https://scicrunch.org/resolver/AB_561053)          (1:10) dilution, on 0.05 mg/ml lysates for Wes

  Antibody                           anti-Src p-Tyr418 (rabbit polyclonal)                                     Sigma-Aldrich                                                    \#44660G;\                                                                                (1:10) dilution, on 0.05 mg/ml lysates for Wes
                                                                                                                                                                                RRID:[AB_1500523](https://scicrunch.org/resolver/AB_1500523)                              

  Antibody                           anti-Shp1 p-Tyr564 (rabbit monoclonal)                                    Cell Signaling Technology                                        \#8849, clone: D11G5;\                                                                    (1:10) dilution, on 0.2 mg/ml lysates for Wes
                                                                                                                                                                                RRID:[AB_11141050](https://scicrunch.org/resolver/AB_11141050)                            

  Antibody                           anti-Shp2 p-Tyr542 (rabbit polyclonal)                                    Cell Signaling Technology                                        \#3751;\                                                                                  (1:10) dilution, on 0.2 mg/ml lysates for Wes
                                                                                                                                                                                RRID:[AB_330825](https://scicrunch.org/resolver/AB_330825)                                

  Antibody                           anti-Shp2 p-Tyr580 (rabbit polyclonal)                                    Cell Signaling Technology                                        \#3703; RRID:[AB_2174962](https://scicrunch.org/resolver/AB_2174962)                      (1:10) dilution,\
                                                                                                                                                                                                                                                                          on 0.2 mg/ml lysates for Wes

  Antibody                           anti-Syk p-Tyr525/6 (rabbit polyclonal)                                   Cell Signaling Technology                                        \#2711;\                                                                                  (1:50) dilution, on 0.2 mg/ml lysates for Wes
                                                                                                                                                                                RRID:[AB_2197215](https://scicrunch.org/resolver/AB_2197215)                              

  Antibody                           anti-SH-PTP1/Shp-1 (rabbit polyclonal)                                    Santa Cruz                                                       sc-287 (C19); RRID:[AB_2173829](https://scicrunch.org/resolver/AB_2173829)                (1:1000)

  Antibody                           anti-SH-PTP2/Shp-2 (rabbit polyclonal)                                    Santa Cruz                                                       sc-280 (C18); RRID:[AB_632401](https://scicrunch.org/resolver/AB_632401)                  (1:1000)

  Antibody                           anti-phosphotyrosine (mouse monoclonal)                                   Merck-Millipore                                                  05--321, clone 4G10;\                                                                     (1:1000)
                                                                                                                                                                                RRID:[AB_309678](https://scicrunch.org/resolver/AB_309678)                                

  Antibody                           anti-human G6b-B (mouse monoclonal)                                       other                                                            clone 17--4                                                                               10 µg/ml, custom-made lab reagent

  Peptide, recombinant protein       purified human IgG-Fc fragment                                            Bethyl Laboratories                                              P80-104                                                                                   

  Peptide, recombinant protein       recombinant Mouse Syndecan-2/CD362 protein, CF                            R&D Systems                                                      6585-SD-050                                                                               

  Peptide, recombinant protein       recombinanthuman Agrin protein, N-terminal, CF                            R&D Systems                                                      8909-AG-050                                                                               

  Peptide, recombinant protein       rec. human laminin 111                                                    Biolamina                                                        LN111-02                                                                                  

  Peptide, recombinant protein       rec. human laminin 411                                                    Biolamina                                                        LN411-02                                                                                  

  Peptide, recombinant protein       rec. human laminin 421                                                    Biolamina                                                        LN421-02                                                                                  

  Peptide, recombinant protein       rec. human laminin 511                                                    Biolamina                                                        LN511-02                                                                                  

  Peptide, recombinant protein       rec. human laminin 521                                                    Biolamina                                                        LN521-02                                                                                  

  Chemical compound, drug            heparan sulfate proteoglycan                                              Sigma-Aldrich                                                    H4777                                                                                     alternative name: perlecan

  Chemical compound, drug            heparin                                                                   Iduron                                                           HEP001                                                                                    <https://iduron.co.uk/product/Heparin-1>

  Chemical compound, drug            heparin oligosaccharide dp4                                               Iduron                                                           HO04                                                                                      <https://iduron.co.uk/product/Heparin-1>

  Chemical compound, drug            heparin oligosaccharide dp8                                               Iduron                                                           HO08                                                                                      <https://iduron.co.uk/product/Heparin-1>

  Chemical compound, drug            heparin oligosaccharide dp12                                              Iduron                                                           HO12                                                                                      <https://iduron.co.uk/product/Heparin-1>

  Chemical compound, drug            heparin oligosaccharide dp20                                              Iduron                                                           HO20                                                                                      <https://iduron.co.uk/product/Heparin-1>

  Chemical compound, drug            2-O-desulphated heparin                                                   Iduron                                                           DSH001/2                                                                                  

  Chemical compound, drug            6-O-desulphated heparin                                                   Iduron                                                           DSH002/6                                                                                  

  Chemical compound, drug            N desulphated heparin                                                     Iduron                                                           DSH003/N                                                                                  

  Chemical compound, drug            N-desulphated re N-acetylated heparin                                     Iduron                                                           DSH004/Nac                                                                                

  Chemical compound, drug            heparan sulphate                                                          Iduron                                                           GAG-HS01                                                                                  

  Chemical compound, drug            HS fraction III approx. mol. wt. 9 kDa                                    Iduron                                                           GAG-HS III                                                                                

  Chemical compound, drug            APAC                                                                      Aplagon Oy                                                                                                                                                 

  Chemical compound, drug            heparinase III (heparitinase I) *Flavobacterium heparinum* (EC 4.2.2.8)   AMSBiotechnology                                                 AMS.HEP-ENZ III                                                                           

  Chemical compound, drug            Heparin−biotin sodium salt                                                Sigma-Aldrich                                                    B9806-10MG                                                                                

  Chemical compound, drug            fibronectin                                                               Cabiochem                                                        Cat \#341631                                                                              

  Chemical compound, drug            fibrinogen                                                                Enzyme Research Laboratories                                     Fib 3 3496L                                                                               

  Chemical compound, drug            collagen I                                                                Takeda                                                           1130630                                                                                   collagen reagens horms

  Chemical compound, drug            Cultrex Mouse Collagen IV                                                 Trevigen                                                         3410-010-01                                                                               purchased via R & D Systems

  Chemical compound, drug            Laminin from EHS murine sarcoma basement membrane                         Sigma-Aldrich                                                    L2020                                                                                     refers to mouse laminin-111 in this study

  Chemical compound, drug            streptavidin                                                              Sigma-Aldrich                                                    S4762                                                                                     

  Software                           Cell Profiler (2.2.0)                                                     Broad Institute                                                  <http://cellprofiler.org/> RRID:[SCR_007358](https://scicrunch.org/resolver/SCR_007358)   

  Software                           Fiji                                                                      [PMID: 22743772](https://www.ncbi.nlm.nih.gov/pubmed/22743772)   <https://imagej.net/Fiji>;\                                                               
                                                                                                                                                                                RRID:[SCR_002285](https://scicrunch.org/resolver/SCR_002285)                              
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mice {#s4-1}
----

*Mpig6b* (*Mpig6b^--/^*^--^) and *Mpig6b^diY/F^* knock-in (*Mpig6b^diYF/diYF^*) mice were generated on a C57BL/6 background by Taconic Artemis (Cologne, Germany) as previously described ([@bib29]; [@bib50]). Control mice were pure C57BL/6 (*Mpig6b^+/+^*), referred to as WT. All procedures were undertaken with UK Home Office approval (project license No P46252127) in accordance with the Animals (Scientific Procedures) Act of 1986.

Reagents and antibodies {#s4-2}
-----------------------

See Key Resources Table for information on the sources of key reagents used in this study.

p-nitrophenyl phosphate (pNPP) and goat anti-human IgG--HRP antibody were obtained from Sigma-Aldrich, Dorset, UK. The semisynthetic macromolecular conjugate of unfractionated heparin and a human serum albumin, APAC, was from Aplagon Oy, Helsinki, Finland. Blocking medium (2.5% horse serum) and 3,3\'-diaminobenzidine tetrahydrochloride (DAB) peroxidase substrate for immunohistochemistry were purchased from Vector Laboratories, Peterborough, UK and 3,3,5,5 tetramethylbenzidine (TMB) was from BD Biosciences, Wokingham, UK. Polyclonal phospho-specific G6b-B antibodies were generated by Biogenes, Berlin, Germany. Phalloidin-Alexa 488 was from Invitrogen Life Technologies, Paisley, UK. All other antibodies and chemicals were either purchased or generated as previously described ([@bib50]).

Constructs {#s4-3}
----------

*Recombinant proteins:* the cDNA encoding the mouse G6b-B extracellular domain was amplified by PCR using the primers GATC AAGCTT ATG GCC TTG GTC CTG CCG CTG (forward) and GATC GGATCC ACT TAC CTG T CTC GTA CCC GTG GGT AGA TCC (reverse) from a mouse megakaryocyte cDNA library template. The PCR product was cleaved using Hind III and Bam HI and ligated into pCDNA3Ig, which was comprised of the genomic human IgG1 hinge-C2-C3 Fc region cloned into the HindIII and Not I sites of pcDNA3. This creates a construct encoding the extracellular part of G6b, spliced in frame with the IgG1 hinge, producing a G6b-B-Fc chimeric dimer. The resulting protein, mG6b-B-Fc, was expressed in COS-7 cells and then purified via affinity chromatography. The human G6b-B-Fc dimer (hG6b-B-Fc) construct was produced using an identical approach to the murine construct, using the primers GATC AAGCTT ATG GCT GTG TTT CTG CAG CTG (forward) and GATC GGATCC ACTTACCTGT CTG GGG ATA CAC GGA CCC ATG (reverse). Similarly, untagged monomeric G6b-B (residues 18--142) as well as His-tagged versions were produced --- human G6b-B (residues 18--142)-Fc-His6 (expressed as a homodimer) and human G6b-B (residues 18--142)-Fc-His6/Fc-streptagII (heterodimer, monomeric for G6b-B; Peak Proteins Limited, Alderley Park) --- for use in surface plasmon resonance measurements. All human constructs were expressed transiently in HEK293-6E cells.

*Cell culture*: The cDNA encoding the full length of human G6b-B protein was amplified by PCR from a human cDNA library. This PCR fragment was first cloned into the pCR-Blunt vector (Invitrogen), and then subcloned into the pCDNA3 vector, for the expression of untagged G6b-B in heterologous cell systems. Subsequently, the G6b-B mutant that is mutated in the potential heparin binding site (hG6b-B K54D/K58D/R60E/R61E) was generated with the Quick Change Site-directed mutagenesis kit (Agilent Technologies, Stockport, UK).

Immunohistochemistry {#s4-4}
--------------------

Immunohistochemistry stainings were performed according to standard protocols. In brief, frozen mouse tissue sections (Zyagen, San Diego, CA, USA) were thawed and washed once in phosphate buffered saline (PBS). After blocking for 20 min (min) at room temperature (RT), tissues were incubated with mG6b-B-Fc or human IgG-Fc fragment (negative control, 5 µg/ml in PBS) for 75 min at RT. After three washing steps in PBS, slides were fixed in acetone/PFA for 4 min and endogenous peroxidase was blocked with 3% H~2~O~2~ in methanol (5 min). Slides were incubated with anti-human IgG--HRP antibody (1:600 in PBS, 0.1% Tween 20) and the signal developed with DAB substrate. Subsequently, tissue sections were counterstained with hematoxylin. Images were acquired on a Zeiss Axio Scan.Z1 (Zeiss, Cambridge, UK) equipped with an 3CCD color 2MP Hitachi 1200 × 1600 HV-F202SCL camera, using a 10x (NA 0.45) or 20x (NA 0.8) plan apochromat air objective. Images were acquired and exported with the Zeiss Zen software.

Femur sectioning and staining {#s4-5}
-----------------------------

Femurs of mice aged 6--12 weeks were sectioned and stained as described previously ([@bib38]; [@bib71]). In brief, femora were isolated, fixed for 4 hr at 4°C in 4% PFA before being transferred along a sucrose gradient from 10%, 20% and 30%, each for 24 hr. Next, femora were embedded in SCEM medium (Section lab, Hiroshima, Japan) and frozen at −80°C until sectioning. Megakaryocytes were stained with anti-GPIX-Alexa488 antibody, and CD105 was used as an endothelial cell marker. Additional stainings were performed using antibodies against perlecan. Corresponding secondary antibodies were used at a 1:300 dilution. Slides were mounted in Fluoromount G including DAPI (Thermo Fisher Scientific). Recording was performed using a Leica TCS SP8 confocal laser scanning microscope (Leica, Wetzlar, Germany) with an 40x oil objective at 20°C. The numerical aperture (NA) of the objective lens was 1.3 and the software used for data acquisition was LAS X (Leica). Subsequently, images were processed with ImageJ (NIH, Bethesda, MD, USA). No 3D reconstruction, gamma adjustments or deconvolution were performed.

For reconstruction of whole femora sections, single images were taken with a resonant scanner and digitally stitched using LAS X software.

Electron microscopy studies {#s4-6}
---------------------------

Bone marrow samples obtained by flushing mouse femora with 0.1 M sodium cacodylate buffer were fixed in 2.5% glutaraldehyde and embedded in Epon as described ([@bib20]). Thin sections were stained with uranyl acetate and lead citrate, and examined under a JEOL 2100Plus transmission electron microscope at 120 kV (Jeol, Tokyo, Japan). Megakaryocytes were counted on whole transversal sections and the number of cells was expressed as a density per unit area (defined as one square of the grid, i.e. 13 000 μm^2^). Megakaryocytes at stages I, II and III were identified using distinct ultrastructural characteristics: stage I, a cell 10--50 μm in diameter with a large nucleus; stage II, a cell 20--80 μm in diameter containing platelet-specific granules; stage III, a megakaryocyte containing a well-developed demarcation membrane system defining cytoplasmic territories and a peripheral zone. Samples from three mice of each genotype were examined in each case.

Pull-down and identification of the ligand {#s4-7}
------------------------------------------

Venae cavae were dissected from wild-type mice and fat and connective tissue were removed. The endothelial tissue was placed in lysis buffer (10 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1% IGEPAL CA-630, 5 mM Na~3~VO~4~, 0.5 mM 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride, 5 µg/ml leupeptin, 5 µg/ml aprotinin, 0.5 µg/ml pepstatin) and homogenized with a PowerGen homogenizer (Fisher Scientific, Loughborough, UK). Lysates were centrifuged at 13,000 × g for 10 min at 4°C. Supernatants were collected and re-centrifuged under the same conditions. Protein lysate was precleared with Protein G sepharose (PGS, 50% slurry) and human IgG-Fc fragment by agitation for 1 hr at 4°C. The lysate was then split into two samples which received either mG6b-B-Fc or human IgG-Fc fragment (negative control). After 1.5 hr, PGS was added and samples were agitated for another 1.5 hr at 4°C. Finally, PGS was washed three times in lysis buffer and bound proteins were eluted by boiling the PGS pellet for 5 min in 40 µl 2x SDS sample buffer. Samples were then resolved on a NuPage 4--12% Bis-Tris-Gradient Gel (Invitrogen), alongside mG6b-B-Fc (additional negative control) and stained with colloidal coomassie. Bands appearing in the mG6b-B-Fc pulldown, but not in the negative controls, were excised and subjected to mass spectrometry analysis (Orbitrap, Thermo Fisher Scientific, Paisley, UK). Corresponding areas from the control pulldown were cut and analyzed in parallel to account for background signals.

In vitro binding assay {#s4-8}
----------------------

Nunc MaxiSorp plates (Thermo Fisher Scientific) were coated overnight with 50 μl of substrates, diluted in PBS (supplemented with 0.9 mM CaCl~2~ and 0.5 mM MgCl~2~ for laminins) at a concentration of 5 μg/ml. Plates were washed three times with Tris buffered saline (TBS) containing 0.1% Tween 20 (TBS-T) and blocked for 1.5 hr at 37°C with 2% fat free milk in TBS and 0.02% Tween 20. For heparin immobilization, biotinylated heparin (5 μg/ml) was added to streptavidin-coated wells for 1 hr at RT prior to the blocking step. After one washing step, recombinant G6b-B-Fc or human IgG-Fc fragment (negative control) in 3% BSA in TBS-T was added and incubated for 2 hr at 37°C. In competition assays, this incubation step was performed in the presence of the indicated compound. After five washing steps, wells were incubated with HRP-conjugated anti-human IgG antibody for 1 hr at RT at low agitation. Alternatively, monomeric, untagged G6b-B was incubated with anti-G6b-B antibody, and bound complexes were detected with HRP-conjugated anti-mouse IgG antibody. Plates were washed seven times and the signals were developed with TMB. The reaction was stopped by the addition of 2 M H~2~SO~4~ (50 μl/well) and absorbance at 450 nm and 570 nm (background) was measured with a Versa max plate reader (Molecular Devices, Wokingham, UK).

Genome-wide cell-based genetic screening {#s4-9}
----------------------------------------

The cell-based genome-wide genetic screen was performed essentially as described ([@bib74]). In brief, 3 × 10^7^ Cas9-expressing HEK293 cells were transduced with a library of lentiviruses, each encoding a single gRNA from a pool of 90,709 individual gRNAs targeting 18,009 human genes at a low multiplicity of infection of 0.3 to increase the chances that each cell received a single gRNA. Ten million lentivirally transduced cells were selected using a blue fluorescent protein (BFP) marker three days after transduction using fluorescence-activated cell sorting. The sorted cells were placed back into culture and further selected for five days with 2 μg/mL puromycin. On day nine post transduction, 100 × 10^6^ cells were stained with a recombinant protein consisting of the entire ectodomain of biotinylated human G6b-B clustered around phycoerythrin (PE)-conjugated streptavidin for an hour at room temperature. The cells were sorted using an XDP flow sorter and the BFP^+^/PE^-^ population collected, representing \~1% of the total cell population. A total of 600,000 cells were collected from which genomic DNA was extracted, and gRNA sequences were amplified by PCR before their abundances were determined by next generation sequencing. The enrichment of gRNA sequences targeting specific genes in the sorted versus unsorted populations were quantified from the sequence data using MAGeCK software ([@bib44]) as previously described ([@bib74]).

FGFRL1 was used as a positive control for testing the KO of SLC35B2, as it is known to interact with heparan sulfate ([@bib78]). Both G6b-B and FGFRL1 were produced as biotinylated proteins in HEK293 cells by co-transfection with a plasmid encoding a secreted form of the *Escherichia coli* biotin ligase, BirA ([@bib9]). The ectodomain of FGFRL1, aa 1--378, was subcloned from the Origene plasmid sc123844 by PCR with KOD enzyme and primers containing the Not-AscI restriction sites, and cloned into an expression vector containing a rat Cd4 domains 3 and 4 (CD3+4) tag and biotinylatable sequence. Avid fluorescent binding forms of the proteins were generated by conjugating the biotinylated recombinant ectodomain of FGFRL1 with streptavidin-PE. Parental and cells in which SLC35B2 was targeted were stained with the fluorescent reagent as described before ([@bib74]).

Surface plasmon resonance {#s4-10}
-------------------------

The interaction of the recombinant heterodimeric ('monomer') and homodimeric ('dimer') human G6b-B extracellular domain with different ligands was quantified using a BIAcoreTM 8K instrument (GE Healthcare, Little Chalfont, UK). Recombinant G6b-B proteins were immobilized on CM5 sensor chips (GE Healthcare) via an Fc antibody using the Human Antibody Capture Kit (GE Healthcare). Immobilization levels ranged from 7800 to 9000 response units (RU) for the Fc antibody and 3000 to 4000 RU for the G6b-B proteins. Single cycle kinetics (SCK) measurements were undertaken with perlecan, heparin, fractionated HS and dp12. The analytes were injected in increasing concentrations of 0.1, 1, 10, 100 and 1000 nM. Analytes were flowed over the immobilized G6b-B surface at 30 µl/min with 60 s injection time and 60 s dissociation per concentration. In the 'reversed configuration', biotinylated heparin, HS and perlecan were immobilized on streptavidin sensor chips (GE Healthcare); fractionated HS and perlecan were biotinylated using the Lightning-Link Biotinylation kit (Innova Biosciences, Cambridge, UK). Immobilization levels of the biotinylated species were between 900 and 1000 RU. The SCK of 'monomeric' and 'dimeric' G6b-B were evaluated at 0.05, 0.5, 5, 50 and 500 nM. The analytes were flowed over the immobilized peptides at 10 µl/min with 180 s injection time and 360 s dissociation at each concentration. Data were collected from two replicates per experiment type and analyzed using the BIA evaluation software (GE Healthcare). Sensorgrams were double referenced prior to global fitting the SCK sensorgrams to one-to-one binding models in order to determine the rate constant of association (k~on~) and dissociation (k~off~). Binding affinities (K~D~) were calculated from the equation KD = k~off/~k~on~.

Theoretical modeling of G6b-B structure {#s4-11}
---------------------------------------

The G6b-B ectodomain model was generated by submitting the amino acid sequence for G6b-B residues 18--142 to the RaptorX Structure Prediction server (<http://raptorx.uchicago.edu/>) ([@bib35]). Subsequent modeling of the K54D, K58D, R60E, R61E G6b-B mutants and all molecular graphics figure generation was carried out using PyMOL (The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC.). The electrostatic surfaces of both wild-type and mutant G6b-B models were calculated using the APBS suite ([@bib33]).

Crystallography {#s4-12}
---------------

*Production of recombinant G6b-B and the anti-G6b-B Fab fragment.* The G6b-B extracellular domain (ECD) construct encompassing residues 18--133 which include the mutations N32D, S67A, S68A, S69A, T71A was expressed in mammalian HEK293 cells and purified by cation exchange and size-exclusion chromatography. The N32D mutation was used to remove the single potential N-linked glycosylation site that we showed by SDS-PAGE and mass spectrometry to be partially utilized. Intact mass spectrometry also revealed that after having made the N32D mutation, the measured mass of the protein was 948 Da greater than expected, a mass that is consistent with a common O-linked oligosaccharide, 2x sialic acid, galactose, N-acetyl galactosamine. The O-glycosylation was located using TOF-mass spectrometry of a chymotryptic digest of a region encompassing residues 66--80 with the sequence ASSSGTPTVPPLQPF. Each of the five potential sites was mutated to Ala individually in tandem with N32D. This showed that the predominant site was T73, although other Ser or Thr residues could be modified to a lesser degree. Finally, two constructs were made and tested for crystallization, one with four residues mutated to Ala but leaving T73 and one with all five residues mutated to Ala. The construct with four changes crystallized more readily and enabled us to solve the structure. The recombinant anti-G6b-B Fab fragment was also produced in HEK cells, synthetic genes for light and heavy chains were obtained from Invitrogen GeneArt. The G6b-B ECD-Fab complex was formed by incubating the components together for 2 hr at room temperature with G6b-B ECD in a 1.5 molar excess, and the complex was subsequently purified by size-exclusion chromatography. Protein was concentrated to 12 mg/ml in 20 mM Hepes (pH 7.1) and 75 mM NaCl, and finally incubated with 2 mM (10-fold molar excess) of the heparin oligosaccharide dp12 for 1 hr at 4°C prior to setting up the crystallization experiment.

*Production of crystals and solving of structure.* Crystals were grown by vapor diffusion at 20°C in 50 mM MES (pH 6.2), 10% PEG 550MME, 5% v/v glycerol, and 50 mM CaCl~2~, and appeared within 3 days. Crystals were harvested straight out of the growth drop and cryo-cooled in liquid nitrogen. X-ray diffraction data were collected at 100K on beamline I03 at Diamond Light Source and processed using XDS ([@bib34]) and Aimless ([@bib23]) via AutoPROC ([@bib79]). The crystal was in space group C2 with the cell dimensions of a = 183.80 Å, b = 72.34 Å, c = 131.04 Å, β = 124.52°, and extended to 3.1 Å resolution ([Table 2](#table2){ref-type="table"}).

The structure was initially solved by molecular replacement using the program Phaser ([@bib52]) and with a model of the Fab fragment generated from the PDB structure 4K2U ([@bib13]) as the search model. This resulted in the placement of two Fab molecules in the asymmetric unit (Phaser Z-score after translation search = 10.2). Examination of the resulting electron density maps showed substantial unmodeled density in the vicinity of the CDR regions of both Fab molecules, which were interpreted as bound G6b-B ECD. Multiple rounds of model building in Coot ([@bib22]) and refinement using Refmac5 ([@bib58]) resulted in a model encompassing about 90% (101 out of 116 residues) of the of G6b-B ECD chain. Residual density at that stage was identified as a single molecule of dp12-bound heparin, with the density covering 8 of the 12 saccharide units in dp12.

The final model represents a complex of G6b-B ECD, dp12 and Fab fragment chains in the ratio 2:1:2, respectively. The refined structure of G6b-B ECD chain has observable electron density for residues Pro19 to Thr38, Arg43 to Arg83 and Ile91 to Cys129. The G6b-B ECD, as expected, is shown to be a member of the IgV superfamily, with the solved structure comprising two antiparallel β-sheets formed by strands ABDE and A′CC′FG. There is also evidence from the electron density for O-linked glycosylation at Thr73 in both copies of the G6b-B ECD. Final refinement statistics for the G6b-B ECD-dp12-Fab dimer complex are given in [Table 2](#table2){ref-type="table"}.

Size chromatography of G6b-B ECD {#s4-13}
--------------------------------

The G6b-B ECD protein encompassing residues 18--133 (N32D, S67A, S68A, S69A, T71A) was either analyzed immediately, or after incubation with heparin oligosaccharide dp12. A Superdex 75 10/300 GL column (GE Healthcare) was both equilibrated and run in 20 mM Hepes (pH 7.1) and 75 mM NaCl. dp12 was added to the G6b-B ECD at a 4-fold molar excess (150 µM final concentration). After the addition of dp12, the sample was aspirated gently and incubated for 90 min on ice, prior to SEC analysis. Columns were run at 0.3 ml/min, and 400 µl of G6b-B ECD samples were loaded (200 µg). A calibration curve was prepared in the same buffer using conalbumin (75 kDa), ovalbumin (44 kDa), carbonic anhydrase (29 kDa), ribonuclease A (13.7 kDa) and aprotinin (6.6 kDa) (LMM gel filtration standard kit, GE Healthcare). This calibration curve was then used to estimate the molecular weight of both G6b-B ECD and G6b-B ECD +dp12 in order to determine their polymeric states.

Flow-cytometric analysis of heparin binding in transfected CHO cells {#s4-14}
--------------------------------------------------------------------

A5 CHO cells were kindly provided by Ana Kasirer-Friede and Sanford Shattil (University of California, San Diego). A test for mycoplasma contamination was negative. Transfections of WT or mutant hG6b-B into CHO cells were carried out in 6-well plates (3 × 10^5^ cells in 2 ml DMEM medium, supplemented with 10% fetal bovine serum, 2 mM glutamin) using polyethylenimine (Sigma-Aldrich) as described ([@bib21]). Cells were harvested 2 days after transfection by detaching them with accutase, and resuspended in PBS containing 0.2 mg/ml BSA and 0.02% sodium azide. Cells were incubated with heparin-biotin (10 μg/ml) and mouse anti-human G6b-B antibody for 45 min at RT, washed twice, and incubated with streptavidin-PE (BD Biosciences) and anti-mouse-alexa488 antibody (Invitrogen). Cells were fixed with 1% formaldehyde and analyzed on a BD FACSCalibur (BD Biosciences).

Aggregometry {#s4-15}
------------

Platelet rich plasma (PRP) was prepared from blood collected from healthy drug-free volunteers as described previously ([@bib17]). Donors gave full informed consent according to the Helsinki declaration. Ethical approval for collecting blood was granted by Birmingham University Internal Ethical Review (ERN_11--0175 and ERN_15--0973). In brief, 9 volumes of blood were collected into 1 vol of 4% (w/v) sodium citrate solution. Blood was centrifuged at 200 × g for 20 min at RT and PRP was collected. Platelet aggregation was measured using a lumi-aggregometer (Chrono-Log, Abingdon on Thames, UK, Model 700).

Platelet adhesion assay {#s4-16}
-----------------------

This assay was performed as described previously ([@bib3]). In brief, Nunc MaxiSorp plates were coated overnight with 50 μl of substrates, diluted in PBS at a concentration of 10 μg/ml, except for collagen which was used at 2.5 μg/ml. Plates were then washed three times and blocked with 2% BSA in PBS for 1 hr at 37°C. After washing, 50 µl heparinase III (5 mU/ml) or buffer (20 mM Tris-HCl (pH 7.5), 0.1 mg/ml BSA and 4 mM CaCl~2~) were added to each well and incubated for 1.5 hr. After three washing steps, 50 μl of platelet suspension modified Tyrode's buffer, prepared as previously described ([@bib64]), at a concentration of 1 × 10^8^/ml were added and incubated for 1 hr at 37°C. After three washing steps with PBS, 140 µl of substrate solution was added to each well and incubated on a rocker at RT for 40 min. Then, 50 µl of 3M NaOH was added and the signal was quantified 5 min later by measuring the absorbance at 405 nm and 620 nm (background). Percentage of adhesion was calculated by normalizing the measured ODs to the signal obtained by directly lysing 50 µl of platelet suspension.

Flow cytometric analysis of platelet activation {#s4-17}
-----------------------------------------------

5 µl staining solution, containing 1.5 µg fibrinogen-Alexa488 conjugate (Invitrogen) and 1 µg of anti-TLT-1-Alexa 647 antibody (Biotechne, Abingdon, UK) and 5 µl of whole blood were provided in a well of a 96-well plate. Stimulation was started by adding 40 µl of heparin, APAC (0.05 µM final concentration) or buffer, with or without CLEC-2 antibody (3 µg/ml final concentration; Bio-Rad, Oxford, UK). The plate was incubated in the dark for the indicated time and the reaction was stopped by addition of 200 µl 1% ice-cold formalin. Samples were analyzed on a BD Accuri flow cytometer. Platelets were gated using forward and side scatter.

Preparation and culture of mouse megakaryocytes {#s4-18}
-----------------------------------------------

Megakaryocytes were prepared as previously described ([@bib19]; [@bib49]). In brief, bone marrow cells were obtained from mouse femurs and tibias by flushing, and cells expressing lineage-specific surface markers (CD16/CD32, Gr1, B220, or CD11b) were depleted using immunomagnetic beads (sheep anti-rat IgG Dynabeads, Invitrogen). The remaining population was cultured in 2.6% serum-supplemented StemPro medium with 2 mM L-glutamine, penicillin/streptomycin, and 20 ng/mL of murine stem cell factor at 37°C under 5% CO~2~ for 2 days, and for a further 4 days in the presence of stem cell factor and 50 ng/mL thrombopoietin (37°C, 5% CO~2~). Mature megakaryocytes were then enriched using a 1.5%/3% bovine serum albumin gradient under gravity (1 g) for 45 min at room temperature.

Microscopical analysis of platelet and MK adhesion {#s4-19}
--------------------------------------------------

Glass Coverslips (5 mm diameter) were incubated with 50 μl of perlecan (25 μg/ml), fibrinogen (25 μg/ml) or both overnight at 4°C. Surfaces were then blocked with denatured BSA (5 mg/ml) for 1 hr at room temperature. After washing, 50 µl heparinase III (12.5 mU/ml) or buffer were added to each well and incubated for 1.5 hr at 37°C. Platelets (2 × 10^7^/ml, 50 µl) were transferred to the slides and incubated at 37°C for 45 min in a humid atmosphere. Mature megakaryocytes (6 × 10^3^/ml, 100 µl) were incubated for 5 hr. Non-adherent cells were removed by gently washing wells with PBS and adherent cells were fixed with 3.7% paraformaldehyde and permeabilized with 0.2% Triton-X 100 in water. MKs were stained with tubulin-antibody for 1 hr followed by anti-mouse-Alexa-488 and rhodamin-conjugated phalloidin for 30 min, and coverslips were mounted onto microscope slides for imaging using or Antifade Mountant with DAPI (Invitrogen). Platelets were stained with phalloidin-Alexa-488 for 1 hr and coverslips were mounted using Hydromount (National Diagnostics, Nottingham, UK). Images were captured by a Zeiss Axio Observer.Z1/7 epifluorescence microscope using ZEN Software and 20x (MK) or 63x oil immersion (platelet) plan apochromat objectives.

For platelets, each coverslip was imaged in three random areas. For analysis, the central quarter of each field of view was cropped (1024 × 1024 pixels) and ilastik pixel classifier software was used to outline a binary segmentation ([@bib77]). To distinguish touching platelets, KNIME analytic platform was used to identify the centre of individual platelets manually ([@bib5]). These coordinates were used to produce the final segmentation of individual platelets, and platelet size was subsequently calculated.

For MK, three tiles of 3 × 3 images were acquired per coverslip. Average surface area per cell was calculated by analyzing total surface area and number of cells per image by using ImageJ. Both, imaging and analysis were performed blinded.

Western blotting and immunoprecipitation {#s4-20}
----------------------------------------

Washed human or mouse platelets (5 × 10^8^/ml) in the presence of 10 µM integrilin or lotrafiban (integrin αIIbβ3 inhibitors), respectively, were incubated with the respective compound under stirring conditions (1200 rpm, 37°C) for the indicated time. Platelets were lysed by the addition an equal volume of ice cold 2 x lysis buffer and insoluble cell debris was removed by centrifugation for 10 min at 13,000 x g, at 4°C.

For immunoprecipitations, whole cell lysates (WCLs) were precleared using protein A Sepharose (Sigma-Aldrich) for 30 min at 4°C. G6b-B was immunoprecipitated from collagen-WCLs with anti-G6b-B antibody and protein A sepharose overnight at 4°C as previously described ([@bib50]).

WCLs were either boiled in SDS-loading buffer and analyzed by SDS-PAGE (NuPage 4--12% Bis-Tris-Gradient Gel) and traditional western blotting or, for quantitative analysis, analyzed with an automated capillary-based immunoassay platform (Wes, ProteinSimple, San Jose, USA), according to the manufacturer's instructions. Briefly, WCLs were diluted to the required concentration with 0.1X sample buffer, then prepared by adding 5X master mix containing 200 mM dithiothreitol (DTT), 5 × sample buffer and fluorescent standards (Standard Pack 1, PS-ST01-8) and boiled for 5 min at 95°C. Samples, antibody diluent 2, primary antibodies and anti-rabbit secondary antibody, together with luminol S-peroxide mix and wash buffer, were displaced into Wes 12--230 kDa prefilled microplates (pre-filled with separation matrix 2, stacking matrix 2, split running buffer two and matrix removal buffer, SM-W004). The microplate was centrifuged for 5 min at 2500 rpm at room temperature. To start the assays, the capillary cartridge was inserted into the cartridge holder and the microplate placed on the plate holder. To operate Wes and to analyze results, Compass Software for Simple Western was used (version 3.1.7, ProteinSimple). Separation time was set to 31 min, stacking loading time to 21 s and sample loading time to 9 s. Primary antibodies were incubated for 60 min and the High Dynamic Range (HDR) profile was used for detection. For each antibody, a lysate dilution experiment was performed first to confirm the optimal dynamic range of the corresponding protein on Wes. This was followed by an antibody optimization experiment to compare a range of dilutions and to select an antibody concentration that was close to saturation level to allow a quantitative comparison of signals between samples. The optimized antibody dilutions and final lysate concentrations were as indicated in the key resources table.

Statistical analysis {#s4-21}
--------------------

All data are presented as mean ± standard deviation (SD). Statistical significance was analyzed by one-way or two-way ANOVA, followed by the appropriate post hoc test, as indicated in the figure legend, using GraphPad Prism 6 (GraphPad Software Inc, San Diego, CA, USA).

Funding Information
===================

This paper was supported by the following grants:

-   http://dx.doi.org/10.13039/501100000274British Heart Foundation RG/15/13/31673 to Jun Mori, Zoltan Nagy, Alexandra Mazharian, Yotis A Senis.

-   http://dx.doi.org/10.13039/501100000274British Heart Foundation FS/13/1/29894 to Yotis A Senis.

-   http://dx.doi.org/10.13039/501100001659Deutsche Forschungsgemeinschaft VO 2134-1/1 to Timo Vögtle.

-   http://dx.doi.org/10.13039/501100000265Medical Research Council Confidence in Concept 2018 to Timo Vögtle, Yotis A Senis.

-   http://dx.doi.org/10.13039/100004440Wellcome 206194 to Gavin J Wright.

-   http://dx.doi.org/10.13039/501100000274British Heart Foundation FS/15/58/31784 to Alexandra Mazharian.

-   http://dx.doi.org/10.13039/501100001665Agence Nationale de la Recherche ANR-17-CE14-0001-01 to Anita Eckly.

The authors would like to thank all of the voluntary blood donors and the phlebotomists as well as Jamie Webster from the University of Birmingham Core Protein Expression Facility and Silke Heising for excellent technical assistance, Jeremy A Pike for assistance with image and KNIME analysis, the Advanced Mass Spectrometry Facility, and all members of the Biomedical Services Unit for exceptional maintenance of the mouse colonies.

Additional information {#s5}
======================

No competing interests declared.

was an employee at Sygnature Discovery Limited at the time of the study, performing surface plasmon resonance experiments as part of a paid service.

is an employee at Sygnature Discovery Limited, performing surface plasmon resonance experiments as part of a paid service.

is CSO and shareholder of Aplagon Oy, Helsinki, Finland.

receives research funding from Aplagon Oy, Helsinki, Finland.

is an employee at Peak proteins Limited, performing crystallography and protein expression studies as part of a paid service.

is an employee at Peak proteins Limited, performing crystallography and protein expression studies as part of a paid service.

is an employee at Peak proteins Limited, performing crystallography and protein expression studies as part of a paid service.

is an employee at Peak proteins Limited, performing crystallography and protein expression studies as part of a paid service.

is an employee at Peak proteins Limited, performing crystallography and protein expression studies as part of a paid service.

is employee at Peak proteins Limited, performing crystallography and protein expression studies as part of a paid service.

is CEO of Peak proteins Limited, performing crystallography and protein expression studies as part of a paid service.

Formal analysis, Funding acquisition, Validation, Investigation, Methodology, Writing---original draft, Writing---review and editing.

Formal analysis, Investigation, Methodology, Writing---review and editing.

Formal analysis, Funding acquisition, Investigation, Methodology, Writing---review and editing.

Formal analysis, Investigation, Methodology, Writing---original draft, Writing---review and editing.

Investigation, Writing---review and editing.

Investigation, Writing---review and editing.

Investigation, Writing---review and editing.

Investigation.

Investigation, Methodology, Writing---original draft.

Investigation, Methodology, Writing---original draft.

Resources, Writing---review and editing.

Resources, Writing---review and editing.

Methodology, Writing---review and editing.

Data curation, Formal analysis, Investigation, Methodology, Writing---review and editing.

Supervision, Investigation.

Investigation.

Investigation, Writing---review and editing.

Investigation.

Investigation.

Formal analysis, Supervision, Methodology.

Investigation, Writing---review and editing.

Formal analysis, Writing---review and editing.

Formal analysis, Funding acquisition, Investigation, Methodology, Writing---original draft, Writing---review and editing.

Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing---review and editing.

Formal analysis, Validation, Investigation, Methodology, Writing---original draft.

Formal analysis, Investigation.

Investigation, Writing---review and editing.

Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Methodology, Writing---original draft, Project administration, Writing---review and editing.

Human subjects: Blood was collected from healthy drug-free volunteers. Donors gave full informed consent according to the Helsinki declaration. Ethical approval for collecting blood was granted by Birmingham University Internal Ethical Review (ERN_11-0175 and ERN_15-0973).

Animal experimentation: All animal procedures were undertaken with the U.K. Home Office approval (project license No P46252127) in accordance with the Animals (Scientific Procedures) Act of 1986.

Additional files {#s6}
================

10.7554/eLife.46840.041

Data availability {#s7}
=================

Diffraction data have been deposited in PDB under the accession code 6R0X.

The following dataset was generated:

TimoVögtleSumanaSharmaJunMoriZoltanNagyDanielaSemeniakCyrilScandolaMitchellJ GeerChristopherW SmithJordanLaneScottPollackRiittaLassilaAnnukkaJouppilaAlastairJ BarrDerekJ OggTinaD HowardHelenJ McMikenJuliWarwickerCatherineGehRachelRowlinsonWMark AbbottAnitaEcklyHaraldSchulzeGavinJ WrightAlexandraMazharianKlausFüttererSundaresanRajeshMichaelR DouglasYotisA Senis2019G6b-B in complex with dp12Protein Data Bank6R0X

The following previously published datasets were used:

CaiZYarovoiS VZhuZRauovaLHayesVLebedevaTLiuQPonczMArepallyGCinesD BGreeneM I2015Crystal structure of platelet factor 4 complexed with fondaparinuxProtein Data Bank4R9W

DahmsS OMayerM CRoeserDMulthaupGThanM E2015X-ray structure of the amyloid precursor protein-like protein 1 (aplp1) e2 domain in complex with a heparin dodecasaccharideProtein Data Bank4RDA

FukuharaNHowittJ AHussainS AHohenesterE2008Drosophila Robo IG1-2 (monoclinic form)Protein Data Bank2VRA

PellegriniLBurkeD FvonDelft FMulloyBBlundellT L2000Crystal structure of a ternary fgf1-fgfr2-heparin complexProtein Data Bank1E0O

SchlessingerJPlotnikovA NIbrahimiO AEliseenkovaA VYehB KYayonALinhardtR JMohammadiM2000Crystal structure of a ternary fgf2-fgfr1-heparin complexProtein Data Bank1FQ9

10.7554/eLife.46840.059

Decision letter

Bjorkman

Pamela J

Reviewing Editor

California Institute of Technology

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Heparan sulfates are critical regulators of the inhibitory megakaryocyte-platelet receptor G6b-B\" for consideration by *eLife*. Your article has been reviewed by Philip Cole as the Senior Editor, a Reviewing Editor, and three reviewers. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This manuscript reports on novel aspects of the biology of G6b-B, a receptor highly expressed in platelets and megakaryocytes. The authors provide a strong rationale for the biomedical relevance of G6b-B: its loss or absence has been shown to result in thrombocytopenia, platelet dysfunction, and bleeding in mice and humans. The authors\' had a compelling goal for this work: to identify the physiologic ligand for G6b-B, which has previously been unknown. Vӧgtle et al., provide strong evidence that the heparan sulfate glycosaminoglycan (HS-GAG) is the ligand of the G6b-B receptor and provide both structural and functional evidence of the involvement of this interaction in platelet function through the induction of intracellular ITIM-associated downstream signaling by the tyrosine phosphatases Shp1 and Shp2. Strengths of this paper include the use of a diversity of methods to probe the structure and function of G6b-B, including proteomics, a CRISPR genetic screen, crystallography, and in vitro biochemical studies.

The manuscript is well written with regards to the in vitro ligand interaction and structural data. However, this paper would strongly benefit from expanding upon the physiological relevance of the G6b-B-HS/perlecan interaction in bone marrow resident megakaryocytes and in platelets. In addition, in a number of instances the claims made in this manuscript are not adequately supported by the data.

Essential revisions:

1\) The sulfation pattern within the GAG-domains, as well as their length and spacing, contribute to the structural heterogeneity of HS and create specific binding sites for protein ligands. The distribution, length, and modification level of such domains appear to be tightly regulated in a tissue/cell-specific fashion suggesting that the regulatory role of HS occurs in a spatiotemporal manner by interacting with unique arrays of protein ligands in different tissues and at different developmental/pathological stages. The structural data show Heparin binding to G6b-B. Biological assays use perlecan, heparin and APAC. Heparin and perlecan do not bind tightly to platelets, whereas APAC does. These molecules differ substantially in HS sequence and structure. The authors do not address the differences. Also, heavy O-glycosylation of G6b-B could affect binding. This has to be considered and at least discussed in the paper.

2\) Figure 1: Femur bone marrow tissue sections should be included in immunohistochemical analyses of G6b-B ligand expression. Overview sections would be helpful in all organs.

3\) Figure 8: Can the finding in A be replicated under flow conditions? It would be interesting to test spreading using human platelets. The immunofluorescent micrographs in figure 8C must include more than 2 platelets per field to be convincing. The number of cells analyzed in the figure legend of the spreading should be quantified (Figure 8C).

4\) Given the mass spec data described in Table 1, why was laminin excluded from the adhesion assays of Figure 8? Moreover, what is the explanation for heparinase treatment increasing the adhesion of G6b-/- mouse platelets (figure 8B) and also affecting their spreading (Figure 8C)? How might HS have an effect on these knockout platelets? Is there another receptor on platelets binding to the backbone of perlecan?

5\) Is there a difference in glycosylation of the G6b-B receptor between megakaryocytes and platelets, which may result in profound differences in binding affinities? Data on the G6b-B-HS/perlecan interaction in megakaryocyte function are lacking, especially given the emphasis on this point in the introduction and Discussion section. The conclusion that megakaryocytes are activated by the interaction is hard to draw from the presented results. Megakaryocytes could be always active in the bone marrow. And how might this translate into the defects seen in G6b-B-deficient platelets?

6\) Figure 9: The context of megakaryocyte G6b-B interactions is an important point and yet barely identifiable by the micrographs of Figure 9A,B. It is not clear which mouse phenotype is shown in Figure 9A and B. If only control samples are shown, results from both phenotypes should be demonstrated. It is unclear if there are differences in megakaryocyte number or distribution. Overview data of bone marrows would be helpful. In subsection "Biological effects of perlecan, heparin and HS on platelets and MKs" the sentence: \"we found very few WT and G6b-/- MKs adhered to perlecan-coated surface formation\", is unclear. Did the authors quantify the distance between perlecan surfaces and megakaryocytes in the entire femur sections? Again, overview sections and quantification would be helpful. The authors show differences in megakaryocyte size between WT and KO mice when cultured in the presence of different substrates. This difference could be due to different stages of maturation and differentiation, as the images suggest. Is there any difference in the maturation of megakaryocyte between phenotypes?

7\) In Figure 9C, number of cells quantified would again be good information to have in the figure legend. Axes should be added to aggregation graphs. Control (with no stimulation) should be shown. The data can be consolidated in a more palatable graph. Does plasma have an impact on HS binding to G6b-B?

8\) The authors observe that perlecan does not seem to have an effect on either platelet aggregation (Figure 10) or G6b-B phosphorylation (Figure 12), likely due to the need for the proteoglycan to be immobilized on a surface, rather than in suspension. The effects of perlecan on platelet G6b-B signaling is a major component of this paper and should be elucidated by allowing platelets to adhere on immobilized perlecan prior to lysis and blotting for phosphotyrosine. The conclusion that G6b-B and its ligand perlecan inhibit activation in platelets is not really supported by direct evidence. The evidence is based on APAC binding to platelets, hence more direct evidence would be helpful.

9\) The text corresponding to Figure 11 and Figure 12 needs to be streamlined, as it is hard to follow. The figures could be edited/consolidated for clarification.

10\) Were data in Figure 11 obtained with washed platelets or platelets in plasma? Signaling is not induced by soluble perlecan. Can the authors immobilize perlecan to test if immobilized perlecan induces signaling?

11\) In Figure 4---figure supplement 1, why do CHO cells transfected with G6b-B mutant bind less efficiently than mock transfected cells? One can suppose a dominant negative effect? CHO cells constitutively express G6b-B?

12\) In Figure 8, given the important reduction in platelet binding onto fibrinogen and collagen coated surfaces in the presence of intact immobilized perlecan and given the percentage of adhesion, one would expect that, after removing HS from perlecan in the same settings, platelet adhesion to both ECMs should increase in an additive manner above the level of the two ECMs alone. This is further supported by the previous finding of Lord et al., 2011 showing that plaletet binding to C-terminal fragment of perlecan, endorepellin, enhances collagen-mediated platelet responses. Please comment.

13\) The results shown in Figure 8B showed a negligible interaction of both WT and G6b-/- platelets to perlecan, this raises the doubt of the significance of the experiments shown in Figure 8C. Further, the differences in platelet area might be due to the intrinsic differences in platelet volume previously demonstrated by the same authors. Further, it is not clear how removing the HS and thus exposing the core protein of perlecan to platelet a2b1 platelet spreading should decrease.

14\) There is a lack of correspondence between the text and the panels shown in Figure 9. Although potentially interesting, the data on megakaryocytes appear too preliminary and do not add significance to the work.

15\) The data on the opposite effects of soluble and conjugated heparin on platelet function are interesting. The authors concluded that these are due to a differential engagement of G6b-B and related downstream related signaling. To definitely prove the fundamental relevance of the SHPs-related inhibitory signaling, the authors should perform the experiments on platelet function with SHP1/2 KO platelets and by using SHPs specific inhibitors.

Concerns about interpretation:

1\) While the authors demonstrate that perlecan is a ligand for G6b-B, their claim that this is the physiologically relevant ligand is not adequately supported. Given that prior work from mice and humans has demonstrated that the phenotype of reduced/absent G6b-B includes (1) decreased in vitro platelet aggregation/activation and (2) thrombocytopenia, it would seem logical to attempt to identify the ligand in lysates from tissues that would be relevant for those phenotypes. This would correspond to (1) blood/plasma (where platelets would be activated) or (2) bone marrow (where platelets are produced). Instead the authors looked for a G6b-B ligand in vena cava lysates; no rationale was provided as to the relevance of this to the human or mouse G6b-B knock out phenotypes. In fact, the authors note that their identified ligand perlecan would be inaccessible to platelets in intact blood vessels, making it hard to imagine that this would be a relevant ligand for platelet aggregation/activation.

2\) Furthermore, additional information is needed to validate perlecan as a hit of the immunoprecipitation proteomics experiment. The hits from the G6b-B pulldown are listed in order of a \"score\" in Table 1, but it is not clear how the authors determined or defined this score. The authors mention that proteins that were \"prominently present in the negative control\" were not included in their list. It would be preferable if they could provide a complete data set for their proteomics results, and calculate a fold enrichment of the identified proteins/peptides in their experimental vs control condition. A reverse immunoprecipitation experiment (pulling down perlecan with an antibody and seeing if G6b-B is pulled down) would be a very useful experiment to confirm these findings.

3\) Further experimental detail is also needed in order to support the authors\' claim that heparan sulfate and not chondroitin sulfate mediates binding of G6b-B to perlecan. The CRISPR knock out screen is suggestive, as it resulted in a number of hits in genes in the heparan sulfate biosynthesis pathway. However, only one hit from this screen was specifically validated by flow cytometry. It would be useful to validate a few more of the hits by making targeted CRISPR knock outs, and specifically to individually target EXTL3 and CSGALNACT~1/2~ (which are the enzymes that commit tetrasaccharide precursors to either heparan sulfate or chondroitin sulfate), and then look for G6b-B binding to the knock down cells by flow cytometry as in Figure 3C. It would also be helpful to generate a perlecan CRISPR HEK293 knock out and test for G6b-B binding by flow.

4\) Finally, the functional data that are provided here lead the authors to conclude that the function of G6b-B is to inhibit platelet activation in the presence of perlecan heparan sulfate. Given that the phenotype of decreased/absent G6b-B is bleeding and decreased platelet activation, it is surprising that the in vitro experiments suggest that absence of G6b-B would result in excessive platelet activation. This seeming contradiction calls in to question whether perlecan heparan sulfate is truly the physiologically pertinent ligand for the clinical phenotype.

10.7554/eLife.46840.060

Author response

*\[...\] The manuscript is well written with regards to the* in vitro *ligand interaction and structural data. However, this paper would strongly benefit from expanding upon the physiological relevance of the G6b-B-HS/perlecan interaction in bone marrow resident megakaryocytes and in platelets. In addition, in a number of instances the claims made in this manuscript are not adequately supported by the data.*

We want to thank the editors and the reviewers for critical evaluation of our manuscript. Please find our answers to the reviewer's questions below. We have made substantial changes to the manuscript by incorporating new data and also by rephrasing the text and by providing additional information, as requested by the reviewers. We hope the reviewer feel that improved version of the manuscript is suitable for publication in *eLife*.

> Essential revisions:
>
> 1\) The sulfation pattern within the GAG-domains, as well as their length and spacing, contribute to the structural heterogeneity of HS and create specific binding sites for protein ligands. The distribution, length, and modification level of such domains appear to be tightly regulated in a tissue/cell-specific fashion suggesting that the regulatory role of HS occurs in a spatiotemporal manner by interacting with unique arrays of protein ligands in different tissues and at different developmental/pathological stages. The structural data show Heparin binding to G6b-B. Biological assays use perlecan, heparin and APAC. Heparin and perlecan do not bind tightly to platelets, whereas APAC does. These molecules differ substantially in HS sequence and structure. The authors do not address the differences. Also, heavy O-glycosylation of G6b-B could affect binding. This has to be considered and at least discussed in the paper.

We thank the reviewer for highlighting these important points related to structural diversity of HS-GAGs that regulate ligand-receptor interactions and the possible implications in pathological settings. We have added two major paragraphs to this effect in the Discussion section.

Regarding the binding affinities of heparin, HS and perlecan to recombinant G6b-B, using SPR, we demonstrate that the binding affinities of heparin and HS are comparable, whereas perlecan is slightly lower. This may be due to structural differences in the perlecan associated HS chains, as raised by the reviewer.

Although G6b-B is O-glycosylated, our crystal structure shows that the glycosylation sites are all spatially well separated from the ligand binding surface, and are not likely to sterically impede ligand binding. In addition, all the recombinant G6b-B molecules used in this study were produced in a mammalian cell line and are glycosylated as well. Hence, we currently have no evidence that glycosylation would affect ligand binding. We have added this information to the Discussion section.

> 2\) Figure 1: Femur bone marrow tissue sections should be included in immunohistochemical analyses of G6b-B ligand expression. Overview sections would be helpful in all organs.

Femur bone marrow sections have been added to Figure 1. Overview sections are shown in Figure 1---figure supplement 1 and Figure 1---figure supplement 2.

> 3\) Figure 8: Can the finding in A be replicated under flow conditions? It would be interesting to test spreading using human platelets. The immunofluorescent micrographs in figure 8C must include more than 2 platelets per field to be convincing. The number of cells analyzed in the figure legend of the spreading should be quantified (Figure 8C).

Platelets do not adhere or spread well on perlecan, as originally described by Whitelock and co-workers (Lord et al., 2009). Thus, we struggled to observe any platelets on a perlecan-coated surface under various conditions tested. It is for this reason that we tried co-coating with perlecan and either fibrinogen or collagen. It is only when we treated perlecan with heparinase III that we observed more platelets adhering and spreading to a greater extent on various surfaces, fitting with our model that this is due to negative signalling via G6b-B.

For reasons given above, we have yet to optimize conditions for platelet flow adhesion studies, which will take a substantial amount of time. We are also starting to use purified perlecan and perlecan fragments provided by Prof Whitelock. Data is not ready to present at this stage, but will form the basis of a follow-up study.

We have included new human platelet spreading data (Figure 8C), demonstrating that human platelets adhere, but do not spread on perlecan. Heparinase III treatment increased surface area of platelets, but average size was much smaller than platelets spreading on fibrinogen, which served as a positive control.

Due to the low number of platelets adhering to perlecan, it is difficult to find more than two platelets in close proximity. We would need to use a lower magnification objective to show multiple platelets, which would result in a loss of structural details of the depicted platelets. Since we provide a quantitative analysis of platelet size, we kept the same representative immunofluorescent micrographs, to illustrate qualitative changes in platelets under different conditions. We also added dot plots for all cells analysed as a Figure 8---figure supplement 1.

We have added platelet numbers quantified to figure legend.

> 4\) Given the mass spec data described in Table 1, why was laminin excluded from the adhesion assays of Figure 8? Moreover, what is the explanation for heparinase treatment increasing the adhesion of G6b-/- mouse platelets (figure 8B) and also affecting their spreading (Figure 8C)? How might HS have an effect on these knockout platelets? Is there another receptor on platelets binding to the backbone of perlecan?

Although laminins were identified in our proteomic analysis (Table 1), we did not detect any interaction between recombinant G6b-B and various forms of laminin in our in vitro binding assay (Figure 2A), thus we did not pursue further. We suspect the reason for the high laminin signal in our G6b-B pulldown is due to indirect association with laminin via perlecan, which was pulled down. It is well established that laminin interacts with perlecan (Battaglia et al., 1992).

Results from the adhesion and spreading experiments with WT and G6b-B KO platelets on perlecan (Figure 8 D) indeed suggests platelet binding to the perlecan core or HS side chains via other receptors. The obvious candidate for binding to the perlecan protein core is the integrin α2β1, which has previously been shown to bind to the C-terminus of perlecan, called endorepellin (Bix et al., 2007). However, we cannot exclude the possibility that platelets also bind to perlecan via other adhesion receptors, either directly, or indirect via perlecan-associated extracellular matrix proteins. The different spreading response of G6b-B KO platelets to perlecan with or without HS chains indeed raises the possibility that HS also binds to other platelet surface receptors, which may be masked in the presence of G6b-B. This is now discussed in the Results section and Discussion section of the revised manuscript.

> 5\) Is there a difference in glycosylation of the G6b-B receptor between megakaryocytes and platelets, which may result in profound differences in binding affinities? Data on the G6b-B-HS/perlecan interaction in megakaryocyte function are lacking, especially given the emphasis on this point in the introduction and Discussion sections. The conclusion that megakaryocytes are activated by the interaction is hard to draw from the presented results. Megakaryocytes could be always active in the bone marrow. And how might this translate into the defects seen in G6b-B-deficient platelets?

We thank the reviewers for raising these excellent points. We currently have no evidence that G6b-B is differentially glycosylated in MKs and platelets. We previously showed that MK and platelet G6b-B migrate at the same molecular weight by Western blotting (Mazharian et al., 2012), suggesting G6b-B is not differentially glycosylated in MKs and platelets. However, further biochemical analysis is required to validate this observation. We have included this information in the Discussion section. Please also refer to our answer to point 1, above.

Although MK functional data is limited, it provides proof-of-principle that G6b-B is also inhibitory in MKs. This is the first time that perlecan has been shown to have a biological effect on MK function, which is mediated through G6b-B. These experiments were challenging due to the limited number of MKs that adhere to perlecan, requiring a substantial amount of optimization that we will now build on in future studies.

We have toned down the potential physiological implications of our MK findings. We agree that MKs may already be in an 'activated' state in the bone marrow, but that G6b-B helps maintain a basal level of activity. A hypothesis we are currently testing is whether contact between MK G6b-B and perlecan in the vessel wall polarizes the MK, providing directionality for proplatelet formation into the vessel lumen. This is now discussed in the revised manuscript.

> 6\) Figure 9: The context of megakaryocyte G6b-B interactions is an important point and yet barely identifiable by the micrographs of Figure 9A,B. It is not clear which mouse phenotype is shown in Figure 9A and B. If only control samples are shown, results from both phenotypes should be demonstrated.

We thank the reviewers for raising these important points and apologize for the confusing labelling and description of the data in the original version of the figure. We have now addressed these points and also rephrased the text and rearranged the subfigures, making it easier to follow.

In the original Figure 9A,B, we had only shown staining of WT bone marrow sections. We have now added data from G6b KO mice and quantification of the number of MKs, as well as MK clustering, in bone marrow sections from both genotypes.

> It is unclear if there are differences in megakaryocyte number or distribution. Overview data of bone marrows would be helpful.

This is an important point: We have now generated novel images taken over the complete mouse femur and stitched the images to get a complete section overview (Figure 9---figure supplement 1). This allowed us to identify MKs over the distinct bone areas and we can now conclude that the MK distribution is comparable between knockout and wildtype animals. Clearly, the number of MKs is significantly higher in G6b KOanimals compared to wildtype controls (Figure 9B). We have clarified this statement in the Results section of the revised manuscript.

In addition, we have added electron microscopy images of MKs in WT and *G6b* KO bone marrow (Figure 9D-E and Figure 9---figure supplement 2), complementing the data above. This data shows, that there is no significant difference in the maturation of MKs in G6b KO mice. In summary, findings demonstrate a profound increase in the number of MKs around perlecan-positive vessels in the bone marrow.

> In subsection "Biological effects of perlecan, heparin and HS on platelets and MKs" the sentence: \"we found very few WT and G6b-/- MKs adhered to perlecan-coated surface formation\", is unclear. Did the authors quantify the distance between perlecan surfaces and megakaryocytes in the entire femur sections? Again, overview sections and quantification would be helpful.

Thank you for pointing this out. We have rephrased the result section and also moved the findings from our in vitro experiment, the seeding of ex vivo-differentiated MKs onto different surfaces (former Figure 9C) into a new Figure (Figure 10), to separate it more clearly from the microscopic analysis of bone marrow sections.

We have not quantified the distance between perlecan surfaces and megakaryocytes, since in our experience a quantification of this kind of interaction in an immunofluorescence image is rather crude method that would not allow us to draw robust conclusions. Instead, we have quantified the localization of MKs at the vessel walls -- where perlecan is located -- in WT and *G6b^-/-^* mice across the bone. We found no major difference between WT and KO mice.

![Relative numbers of MKs located at the vessel.](elife-46840-resp-fig1){#respfig1}

> The authors show differences in megakaryocyte size between WT and KO mice when cultured in the presence of different substrates. This difference could be due to different stages of maturation and differentiation, as the images suggest. Is there any difference in the maturation of megakaryocyte between phenotypes?

We previously showed that G6b-B-deficient MKs differentiate and proliferate normally ex vivo, under the conditions tested (Mazharian et al., 2012), which is now validated by EM analysis of bone marrow sections (Figure 9D-E). There is no evidence to suggest that differences in MK size observed in this experiment are due to developmental defects in the absence of G6b-B. Rather they are due to the ability of MKs to adhere and spread on different surfaces. We have incorporated this into the Discussion section.

> 7\) In Figure 9C, number of cells quantified would again be good information to have in the figure legend.

MK numbers quantified have now been added to Figure 9C legend.

> Axes should be added to aggregation graphs. Control (with no stimulation) should be shown. The data can be consolidated in a more palatable graph. Does plasma have an impact on HS binding to G6b-B?

Axes have been added to aggregation traces in the respective figure. Control, no stimulation, aggregation trace has also been added. We have tried presenting graphs in a more understandable format. We have yet to test the effects of plasma on HS binding by G6b-B.

> 8\) The authors observe that perlecan does not seem to have an effect on either platelet aggregation (Figure 10) or G6b-B phosphorylation (Figure 12), likely due to the need for the proteoglycan to be immobilized on a surface, rather than in suspension. The effects of perlecan on platelet G6b-B signaling is a major component of this paper and should be elucidated by allowing platelets to adhere on immobilized perlecan prior to lysis and blotting for phosphotyrosine. The conclusion that G6b-B and its ligand perlecan inhibit activation in platelets is not really supported by direct evidence. The evidence is based on APAC binding to platelets, hence more direct evidence would be helpful.

The reviewer raises excellent points that we have tried to address. However, the issue is minimal platelet adhesion on perlecan, making it impossible to generate sufficient quantities of platelet lysates for Western blot analysis. We tried addressing this issue by incubating platelets on perlecan/fibrinogen co-coated surfaces, however, data was difficult to interpret due to strong G6b-B phosphorylation by the fibrinogen surface alone.

Furthermore, given the information in Figure 8A, platelets that receive an inhibitory stimulus via the HS/G6b-B interaction, would not be expected to adhere. We also did not observe an increase in G6b-B phosphorylation of the non-adherent fraction of platelets, most likely because only a small subset of platelets makes contact with the surface in a non-synchronized manner.

We respectfully disagree with the reviewer's interpretation that there is no evidence for a role of perlecan regulating platelet function. Figure 8A,B clearly demonstrates an inhibitory effect of the HS side chains of perlecan on platelet adhesion and spreading. The inhibitory effect of perlecan on platelets was previously demonstrated by Whitelock and co-workers (Lord et al., 2009), but the mechanism of action was not known.

> 9\) The text corresponding to Figure 11 and Figure 12 needs to be streamlined, as it is hard to follow. The figures could be edited/consolidated for clarification.

We agree with the reviewer and revised Figures and text. Figure 11 (now Figure 12) and corresponding supplements have been merged into a single figure. The two figure supplements for former Figure 12 (now Figure 13) have been combined into one figure, and redundant data has been removed.

> 10\) Were data in Figure 11 obtained with washed platelets or platelets in plasma? Signaling is not induced by soluble perlecan. Can the authors immobilize perlecan to test if immobilized perlecan induces signaling?

The experiments were performed in mouse blood, diluted 1:10 in Tyrode's buffer -- we have specified this in the Figure legend.

Please see our answer to point 8 above regarding signalling experiment on immobilized perlecan.

> 11\) In Figure 4---figure supplement 1, why do CHO cells transfected with G6b-B mutant bind less efficiently than mock transfected cells? One can suppose a dominant negative effect? CHO cells constitutively express G6b-B?

We thank the reviewer for raising these points. We have now reanalysed data using different settings and found a marginal overcompensation against the G6b-B channel in the data shown, giving rise to this difference. This has been corrected and data replaced from an experiment where this was not the case. CHO cells, do not express G6b-B; we gated on the entire population of mock-transfected cells for the histogram, using them as a negative control for G6b-B-transfected cells. This information has been added to the figure legend.

> 12\) In Figure 8, given the important reduction in platelet binding onto fibrinogen and collagen coated surfaces in the presence of intact immobilized perlecan and given the percentage of adhesion, one would expect that, after removing HS from perlecan in the same settings, platelet adhesion to both ECMs should increase in an additive manner above the level of the two ECMs alone. This is further supported by the previous finding of Lord et al., 2011 showing that plaletet binding to C-terminal fragment of perlecan, endorepellin, enhances collagen-mediated platelet responses. Please comment.

Thank you for raising these points. We suspect this is due to saturating amounts of fibrinogen and perlecan, hence masking an additive effect.

> 13\) The results shown in Figure 8B showed a negligible interaction of both WT and G6b-/- platelets to perlecan, this raises the doubt of the significance of the experiments shown in Figure 8C. Further, the differences in platelet area might be due to the intrinsic differences in platelet volume previously demonstrated by the same authors. Further, it is not clear how removing the HS and thus exposing the core protein of perlecan to platelet a2b1 platelet spreading should decrease.

We thank the reviewer for raising these points. Both we and others have shown that perlecan has an anti-adhesive property that we attribute to the HS-G6b-B interaction (Lord et al., 2009). Importantly, we demonstrate that this anti-adhesive property prevents platelet adhesion to fibrinogen and collagen. Hence, give that perlecan is the most abundant HS proteoglycan in the vessel wall, we disagree that these findings have no relevance.

Differences in spreading on perlecan are not due to the increase in volume of G6b KO platelets. This has been previously demonstrated (Mazharian et al., 2012), and new data has been added that supports this finding, including platelet spreading on fibrinogen, where no increase in volume of G6b KO platelets is observed (new Figure 8D). In addition, size differences between adhered G6b KO and WT platelets is abolished following treatment of perlecan with heparinase III. As mentioned in our answer to point 4, differences in size between WT and G6b KO platelets in the presence of HS points towards to existence of activating HS receptors on the platelet surface, masking the inhibitory effect of G6b-B. This is now clarified in the revised manuscript.

Of note, HS chains are attached to the N-terminus of the perlecan protein core, while endorepellin is found in the C-terminus, hence the α2β1 binding site should be accessible in the presence of the HS chains.

> 14\) There is a lack of correspondence between the text and the panels shown in Figure 9. Although potentially interesting, the data on megakaryocytes appear too preliminary and do not add significance to the work.

We apologize again for the poor wording. We appreciate the reviewers comment and now have revised the figure, data and corresponding text and hope the reviewers find the new version easier to follow. Please also refer to our answer to points 5 and 6 above, regarding the significance of the MK data and the new data included.

> 15\) The data on the opposite effects of soluble and conjugated heparin on platelet function are interesting. The authors concluded that these are due to a differential engagement of G6b-B and related downstream related signaling. To definitely prove the fundamental relevance of the SHPs-related inhibitory signaling, the authors should perform the experiments on platelet function with SHP1/2 KO platelets and by using SHPs specific inhibitors.

We currently do not have Shp1 and Shp2 single or double KO mice. Shp1/2 DKO mice have severe MK developmental defects, making it impossible to interpret functional findings. Although a specific Shp2 inhibitor is now available, a specific Shp1 inhibitor has yet to be developed. We would like to draw the reviewer's attention to the data in our study using mice harbouring loss-of-function mutations in G6b-B. G6b-B diY/F is uncoupled from Shp1 and Shp2 in these mice (Geer et al., 2018), recapitulating the KO phenotype. Our findings clearly demonstrate a lack of an inhibitory effect of APAC on CLEC-2 mediated platelet activation (Figure 12 in the revised the manuscript).

> Concerns about interpretation:
>
> 1\) While the authors demonstrate that perlecan is a ligand for G6b-B, their claim that this is the physiologically relevant ligand is not adequately supported. Given that prior work from mice and humans has demonstrated that the phenotype of reduced/absent G6b-B includes (1) decreased in vitro platelet aggregation/activation and (2) thrombocytopenia, it would seem logical to attempt to identify the ligand in lysates from tissues that would be relevant for those phenotypes. This would correspond to (1) blood/plasma (where platelets would be activated) or (2) bone marrow (where platelets are produced). Instead the authors looked for a G6b-B ligand in vena cava lysates; no rationale was provided as to the relevance of this to the human or mouse G6b-B knock out phenotypes. In fact, the authors note that their identified ligand perlecan would be inaccessible to platelets in intact blood vessels, making it hard to imagine that this would be a relevant ligand for platelet aggregation/activation.

We thank the reviewer for raising these points, however we respectfully disagree that the blood vessel wall, where perlecan is highly expressed, is not relevant to either platelet production or platelet activation. MKs routinely come into contact with sinusoidal blood vessels in the bone marrow and other sites of haematopoiesis, which we show express high levels of perlecan (Figure 9A). Although we have yet to definitely prove it, we hypothesize that the interaction between MK G6b-B and perlecan in sinusoidal blood vessels plays a critical role in regulating polarized proplatelet formation into the vessel lumen. Regarding platelet activation, many of the most potent and well characterized ligands of platelets are found in the vessel wall, including collagen, laminin and fibronectin that platelets only come into contact with following vascular injury. Moreover, the plasma protein VWF binds to exposed collagen and facilitates platelet tethering and adhesion to the site of injury. Thus, it follows that G6b-B, which regulates signalling from the respective receptors for these ligands is also present in the vessel wall, where it can regulate signalling strength from ITAM-containing receptors and integrins.

Although all blood vessels stained with recombinant G6b-B:Fc protein, we chose the vena cava to purify the ligand, as the signals was exceptionally strong in this vessel, and it is a large blood vessel that is easily isolated from negatively staining tissues.

These points are now included in the Results section and Discussion section of the revised manuscript.

However, also referring to point 1 on the heterogeneity of HS above, we recognize the possibility that G6b-B might also interact with other HS proteoglycans, which are located outside the vessel wall -- we have incorporated this into the Discussion section.

> 2\) Furthermore, additional information is needed to validate perlecan as a hit of the immunoprecipitation proteomics experiment. The hits from the G6b-B pulldown are listed in order of a \"score\" in Table 1, but it is not clear how the authors determined or defined this score. The authors mention that proteins that were \"prominently present in the negative control\" were not included in their list. It would be preferable if they could provide a complete data set for their proteomics results, and calculate a fold enrichment of the identified proteins/peptides in their experimental vs control condition. A reverse immunoprecipitation experiment (pulling down perlecan with an antibody and seeing if G6b-B is pulled down) would be a very useful experiment to confirm these findings.

Thank you for raising this point. We have updated Table 1 accordingly, which now depicts a list of all mass spectrometry hits, including those which were prominent in the negative control, most of which were myosins. The protein score was calculated using the SEQUEST HT search algorithm and is the sum of all peptide Xcorr values above the specified score threshold (0.8 + peptide_charge × peptide_relevance_factor where peptide_relevance_factor is a parameter with a default value of 0.4.) The score for each protein in the negative control is also depicted and the fold enrichment was calculated, where possible.

We have also provided the source data files of the experiments showing the complete data set. Please note that occasionally proteins show up in duplicate in this table, due to multiple entries in the Uniprot database and these duplicates were removed in Table 1. It should also be noted that Q3UHL6 -- originally named *Putative uncharacterized protein* in the source data, was subsequently identified to be fibronectin. Table 1 was updated in light of this information.

We agree that a reverse immunoprecipitation would further validate the interaction between G6b-B and perlecan. However, we do not think this is necessary, because the interaction has already been demonstrated by multiple different techniques. Given the time required to establish the correct experimental conditions and with the limited additional value for the already extensive manuscript, we decided not to perform this experiment.

> 3\) Further experimental detail is also needed in order to support the authors\' claim that heparan sulfate and not chondroitin sulfate mediates binding of G6b-B to perlecan. The CRISPR knock out screen is suggestive, as it resulted in a number of hits in genes in the heparan sulfate biosynthesis pathway. However, only one hit from this screen was specifically validated by flow cytometry. It would be useful to validate a few more of the hits by making targeted CRISPR knock outs, and specifically to individually target EXTL3 and CSGALNACT~1/2~ (which are the enzymes that commit tetrasaccharide precursors to either heparan sulfate or chondroitin sulfate), and then look for G6b-B binding to the knock down cells by flow cytometry as in Figure 3C.

As the reviewers mentioned, our CRISPR data clearly shows that the binding is mediated by HS rather than CS. We have also presented additional evidence with biochemical experiments, showing that this interaction on the surface of the cells can be blocked by soluble heparin but not with the same concentration of soluble CS (Figure 3D). Given that we could corroborate the findings from the genetic screens with biochemical methods, we are confident that the interaction at the surface of cells is mediated by HS and not CS.

We have also performed binding of G6B to cells where *EXTL3* has been targeted (cells kept as polyclonal knockout lines) and have observed reduction in binding. As before, we have tested the binding of a HS-binding protein (APLP2, amyloid precursor-like protein 2) to ensure that binding is reduced in the *EXTL3*-targeted polyclonal lines.

![A pentameric version of the G6b-B protein is used.\
CBFH refers to the COMP-β-lactamase-FLAG-3XHis tag. Binding assay was performed nine days post transduction with a sgRNA targeting *EXTL3* as described before (Sharma et al., *Genome Res*., 2018). Two separate batches of cells were infected with the same lentiviral preparation. Representative binding from one experiments is shown. APLP2 is a known HS-binding protein.](elife-46840-resp-fig2){#respfig2}

We would also like to share our unpublished work that points to G6b-B binding specifically to HS rather than CS. We have a protein that specifically binds to chondroitin sulphate and not heparan sulphate. We identified this binding behaviour from a genome-wide screen in HEL cell lines, in which we identified genes specific for CS (*CHST11*) biosynthesis and not for HS. We have a matching HEL cell line screen for G6b-B and we can clearly see the difference in the hits from these two screens. We see the presence of HS-specific genes (*EXTL3, EXT1, EXT2*) only for G6b-B and *CHST11* only for the CS-binding protein. Genes before the commitment step and *SLC35B2* are identified in both screens ([Author response image 3](#respfig3){ref-type="fig"}).

![Comparison of genome-wide screens performed for G6b-B (top panel) vs a CS-binding protein (bottom panel).\
G6B-BLH screened on HEL cells. Note the presence of HS-specific genes (*EXTL3, EXT1, EXT2*) only for G6B and *CHST11* only for the CS-binding protein.](elife-46840-resp-fig3){#respfig3}

When we tested this CS-binding protein on the same EXTL3 KO cell lines from Figure 1, we see that there is no loss in binding ([Author response image 4](#respfig4){ref-type="fig"}).

![Binding behaviour of a CS binding protein.\
Targeting *EXTL3* has no effect on binding whereas targeting *SLC35B2* clearly abrogates binding.](elife-46840-resp-fig4){#respfig4}

Given our experience with the binding behaviours of GAG binding proteins, we usually perform preliminary validation of all GAG binding proteins in *SLC35B2*-KO lines and perform secondary validation with biochemical approaches.

> It would also be helpful to generate a perlecan CRISPR HEK293 knock out and test for G6b-B binding by flow.

We did not specifically identify HSPG2 in the genetic screen and we believe that the binding of G6B on the surface of transformed cell lines is mediated by HS-side chains in *general* rather than HS-side chains on a *particular* protein backbone. A number of cell surface HSPGs can function equivalently on the cell line to provide HS chains and this would preclude the identification of one specific ligand. While the genetic screen itself reveals the HS-binding properties of G6B, it is not well-suited to identify the proteoglycan backbone itself.

> 4\) Finally, the functional data that are provided here lead the authors to conclude that the function of G6b-B is to inhibit platelet activation in the presence of perlecan heparan sulfate. Given that the phenotype of decreased/absent G6b-B is bleeding and decreased platelet activation, it is surprising that the in vitro experiments suggest that absence of G6b-B would result in excessive platelet activation. This seeming contradiction calls in to question whether perlecan heparan sulfate is truly the physiologically pertinent ligand for the clinical phenotype.

We have previously shown that the bleeding phenotype of G6b KO mice is due to a severe reduction in platelet count and down-regulation of the ITAM-containing collagen activation receptor GPVI-FcR γ-chain (Mazharian et al., 2012). G6b null mutations resulted in a similar phenotype in humans (Hofmann et al., 2018). Uncoupling of G6b-B from the tyrosine phosphatases Shp1 and Shp2 also resulted in a similar phenotype in mice (Geer et al., 2018). The reduction in platelet count is primarily due to a reduction in proplatelet production by G6b-B-deficient megakaryocytes. There is an accompanying reduction in platelet half-life in G6b KO mice that likely contributes to the thrombocytopenia. This is due to G6b KO platelets being in a 'pre-activated' state, and being recognized as such by resident macrophages in the spleen and liver, and more rapidly cleared from the circulation compared with control platelets.

The severe reduction in GPVI-FcR γ-chain in platelets from G6b KO and loss-of-function mouse models is a negative feedback mechanism due to tonic signalling from GPVI-FcR γ-chain in the absence of G6bB and collagen. Consequently, platelets from these mouse models do not become activated or adhere normally to collagen, contributing to the bleeding diathesis in these mice (Mazharian et al., 2012). Further evidence of the inhibitory function of G6b-B is hyper-activation of G6b KO platelets to CLEC-2 agonists (Mazharian et al., 2012), and inhibition of GPVI and CLEC-2 signalling by G6b-B in transiently transfected DT40 cells (Mori et al., 2008).

Together with biochemical and structural data presented in our manuscript, we believe this provides compelling evidence that the HS chains of perlecan are indeed ligands of G6b-B. We hypothesize this interaction is critical for regulating proplatelet formation when MKs come into contact with perlecan in sinusoidal blood vessels in the bone marrow, and the platelet response to vascular injury by moderating signalling from ITAM-containing and integrin receptors. Our study lays the foundation for further studies of the physiological relevance of this interaction in mice and humans.
